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General introduction and outline of the thesis
Cutaneous malignant melanoma (CMM) is a malignant skin tumor that develops from 
melanocytes, the pigment producing cells, in the skin. In the last decades melanoma 
incidence rates have been increasing considerably worldwide. In the Netherlands the age-
standardized incidence per 100.000 person-years increased from 11.3 in 1989 to 21.7 in 
2008, with an estimated annual percentage increase of 4.1%.1 By 2008 melanoma ranked 
the 8th most diagnosed cancer in man and 5th most diagnosed cancer in women.2 Age-
standardized mortality increased (albeit to a lesser extent), from 2.2 per 100.000 
person-years in 1989 to 3.9 per 100.000 person-years in 2009, with an estimated annual 
percentage increase of 2.3%.1  
 One of the strongest risk factors for CMM is a familial predisposition. The characteris-
tics and management of melanoma families are the subject of this thesis. This chapter will 
provide a background to the subject by discussing the epidemiology, clinical characteris-
tics, and genetics of melanoma families, as well as the Dutch management guidelines that 
constituted the starting point for this thesis. In the final section, dermoscopy, which has 
been established as an integrated part of the everyday practice of skin surveillance, will be 
introduced. We will start however by providing a short overview of the different melanoma 
risk factors.
Melanoma risk factors
Several melanoma risk factors have been identified. Solar UV is the main environmental 
cause of melanoma.3 At present it is known that the risk of melanoma is significantly 
increased by intermittent exposure: particularly irregular and intense exposure (with 
sunburn), while more regular (chronic) exposure is to some degree inversely associated 
with melanoma.4 Recent studies suggest that chronic UV, intermittent UV and UV 
independent melanomas may represent (clinical, histological, epidemiological and 
molecular) different melanoma subtypes.5
 Much of an individuals’ risk of developing a CMM can be learned by inspection of the 
patients external characteristics. Hair colour (red vs. dark, relative risk of melanoma (RR) = 
1.74 (1.41 – 2.14)), skin colour (fair vs. dark: RR = 2.06 (1.68 – 2.52)), and eye colour (blue vs. 
dark: RR = 1.47 (1.28 – 1.69)), are all associated with melanoma risk, most likely due to their 
correlation with sensitivity to ultraviolet light.6 More strongly correlated with melanoma 
risk are the number of common nevi (RR = 6.89 (4.63 – 10.25) for 101-120 nevi vs. < 15) and 
number of atypical nevi (AN) (RR = 6.36 (3.80 – 10.33) for 5 vs. 0 ).7 The risk of melanoma for 
patients with large congenital nevi is estimated to be about 2.5% to 5%, and highest in the 
first 5 to 10 years of life.8
 The relative risk of melanoma for individuals with a positive family history of melanoma 
has been estimated to be 1.74 (1.41 – 2.14).6 This risk increases considerably in families with 
many melanoma patients. An early study in 23 families with at least two family members 
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with CMM and two relatives with AN, reported a relative risk of CMM of 89 for relatives 
with AN and a relative risk of 229 for relatives with a previous CMM.9 These high relative 
risks are illustrative of the fact that familial susceptibility is likely the strongest risk factor (in 
terms of effect size) for melanoma. 
Familial melanoma
In 1820 Norris was the first to describe familial clustering of melanoma.10 It took almost one 
and a half century before others published similar observations.11 A positive family history 
of melanoma has been reported in 6% to 14% of melanoma patients.12 Familial melanoma 
is defined as the occurrence of at least two first degree relatives with melanoma or three 
melanomas in second-degree relatives.13 Because of the co-occurrence of AN in many of 
the first described melanoma families, the term Familial Atypical Multiple Mole-Melanoma 
(FAMMM) syndrome was adapted.14 The correlation between AN and familial melanoma 
was later shown to be more complex however. AN regularly occur in the general 
population, with an estimated prevalence of 2% to 8% in whites.15-17 In addition AN and 
CMM do not fully co-segregate within FAMMM families.18 This has been well illustrated in 
families with a mutation in the high-penetrance melanoma susceptibility gene CDKN2A; 
relatives with AN have a higher probability of being CDKN2A mutation carrier, but 
mutation carriers may be devoid of AN and mutation negative relatives may have many 
AN.19,20 
The genetics of melanoma susceptibility
So far, two high-penetrance melanoma susceptibility genes associated with an autosomal 
dominant inheritance have been identified. In 1994, CDKN2A(MIM# 600160), located in the 
9p21 region, was the first melanoma susceptibility gene to be identified.21 By using 
different first exons (1α and 1ß) respectively, it encodes two distinct proteins: p16INK4 and 
p14ARF. Both proteins are tumour suppressors involved in cell cycle regulation. 
 Pathogenic germline mutations in the tumor suppressor gene CDKN2A are detected 
in approximately 39% of families with ≥3 melanoma cases.22 CDKN2A mutations have an 
estimated penetrance for CMM of 67% by the age of 80 years.23 In the Netherlands the 
most prevalent CDKN2A germline mutation is a founder mutation (c.225-243del19) that is 
frequently found in the Leiden region, and has therefore been denominated the 
p16-Leiden mutation.24 In addition to an increased melanoma risk, the p16-Leiden 
mutation is associated with a cumulative risk of pancreatic cancer of 17% by age 75.25
Mutations in the second high penetrance melanoma susceptibility gene, the oncogene 
CDK4 (MIM# 123829) have been detected only in few families (estimated 2%).26 CDK4 
germline mutations have a similar impact on melanoma risk as CDKN2A mutations.27
For the majority of families the genetic risk factor has not been fully clarified, but appears 
General introduction | 15
to be the result of a combination of low (e.g. MC1R) and moderate (e.g. MITF) risk modifier 
genes and (possibly) some rare high penetrance genes.28,29 Environmental and lifestyle 
factors (as described above) likely attribute to clustering of melanoma in (some) families, 
and modify expression of genetic risk factors.
 In clinical genetics a distinction is made between families with a proven germline 
mutation (CDKN2A/CDK4): ‘hereditary melanoma’ and families without a (proven) 
germline mutation: ‘familial melanoma’. In families without a proven pathogenic germline 
mutation, melanoma susceptibility is suggested by familial clustering of melanoma 
patients, but cannot be confirmed by genetic testing and therefore remains a clinical 
diagnosis based on pedigree studies alone. 
Clinical characteristics of melanoma patients from melanoma families
Several studies indicate that melanoma patients from melanoma families have an earlier 
age of onset and an increased risk of multiple primary melanomas (MPM). There are also 
reports on a different distribution of histological tumour types in melanoma families; i.e. 
an increased proportion of superficial spreading melanomas, decreased proportion of 
nodular melanomas and a possible absence of acral lentiginous melanomas.30-32 Data on 
the characteristic of melanoma patients specifically from families with a CDKN2A mutation 
are more scarce however. Reports on the age of diagnosis of the first melanoma in these 
families range from 36.3 to 43.3 years.27,33,34 The proportion of mutation carriers who 
develop MPM in the literature ranges from 18.6% to 25.6%, but duration of follow-up was 
not reported in the referred studies.33,35 
In chapter 2 we report a study in which we investigated the clinical and histological char-
acteristics of melanoma(patients) from CDKN2A mutated families in comparison with 
sporadic melanoma patients. In chapter 4 some of the characteristics reported in chapter 
2 were compared between CDKN2A mutated families and CDKN2A wild-type melanoma 
families.
Management
Melanoma patient survival is highly dependend on the stage at diagnosis. Early melanomas 
can be cured by a wide local excision with proper resection margins, but, even though 
promising new therapeutic options are emerging, prognosis is still poor for advanced 
disease.36-38
 Survival outcomes are to a considerable extent predictable based on the histological 
characteristics of the primary tumor, and the presence of lymph node involvement 
(including sentinel node procedure) and (distant) metastases. One of the main histological 
predictive characteristics, first described by Alexander Breslow in 1970 is the tumor 
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(Breslow) thickness, which is the depth of the tumor from the surface of the lesion (stratum 
granulosum) to the deepest point of invasion, expressed in millimeters.39 Breslow thickness 
strongly correlates with survival, which is illustrated by the fact that 10-year survival is 92% 
in case of melanomas ≤ 1.00 mm, and 50% if > 4.00 mm. The presence of ulceration and 
the mitotic rate are additional tumor characteristics correlated with outcome.40 
 Early detection is considered the most effective way to prevent melanoma mortality. 
For this reason, regular surveillance of individuals at high risk of melanoma, such as 
members of melanoma families, is widely advocated.41,42
Effectiveness of melanoma surveillance
In a 2009 review, the U.S. Preventive Services Task Force (USPSTF) reinforced their 2001 
statement that, quote: “evidence is lacking that skin examinations by physicians is effective 
in reducing mortality or morbidity from skin cancer.”.43,44 This statement was predicated on 
the lack of evidence from randomized controlled studies. Although this statement 
addressed skin cancer (including squamous- and basal cell carcinoma) screening of the 
general population, the same argument is brought forward for specific melanoma 
screening or surveillance. Given the fact that an adequately powered, population-based 
randomized controlled trial of screening demonstrating mortality outcomes would 
require approximately 800.000 participants (based on US melanoma-related mortality 
rate), it is unlikely however that a randomized controlled study will ever be conducted.42,43
Several studies have reported that melanomas detected by physicians have a thinner 
Breslow thickness than those detected by patients themselves.45-50 A few studies have 
reported the detection of thinner melanomas in the context of surveillance of melanoma 
families.51-54 Recently convincing arguments for a beneficial effect of screening on 
melanoma survival came from an observational study concerning a population-based 
skin cancer screening project in Schleswig-Holstein, Germany, reporting a significantly 
different and more favourable trend in mortality rates compared to adjacent regions in 
the years following the screening period.55 
 In a recent article the Melanoma Prevention Working Group commented on the 
USPSTF statement that, quote: “…the evidence is compelling enough to support the 
efficacy of targeted screening programs for detecting thinner melanomas, as a proxy 
measure for reduced mortality.”, and, quote: ”…absolute proof is not necessary in the 
public health domain to implement a targeted screening program that has the immediate 
potential to save lives.”.42 
As noted above the effectiveness of surveillance in melanoma families has been 
investigated only in a few studies, mostly with limited numbers of surveillance detected 
melanomas and confined to specialized pigmented lesion clinics.51-54 In chapter 3 we 
investigated the effectiveness of surveillance in CDKN2A mutated families and also 
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address some issues related to the effectiveness of surveillance that have gained little 
attention so far in the literature. In chapter 4 effectiveness of surveillance was assessed in 
families registered at the NFDHT, that were under surveillance throughout the Netherlands.
Management of melanoma families in the Netherlands
In the Netherlands, the first surveillance program for familial melanoma was initiated at 
the Leiden University Medical Center (LUMC) in 1981. Individuals that were invited to the 
program encompassed melanoma patients, their first degree relatives (parents, siblings 
and children) as well as their second degree relatives (grandparents, uncles, aunts, nieces, 
nephews and grandchildren). Starting from the age 12, these relatives are offered (a 
minimum of) annual total skin examinations.
 In 1989 a national registry for familial melanoma was established at the Netherlands 
Foundation for the Detection of Hereditary Tumors (NFDHT) in order to promote the 
detection and surveillance of members of melanoma families throughout the Netherlands. 
Clinicians refer families suspected for familial melanoma to the registry. Genealogical 
studies are performed and all reported malignancies are verified by medical records. If 
criteria for familial melanoma are met, the registry monitors the continuity of the 
surveillance program for all family members with a history of melanoma and their 
unaffected first degree relatives by annually sending letters to the responsible clinician 
(mostly dermatologists). In return these clinicians report the results of surveillance and 
histo-pathologic examination.54,56 
 Starting from 2000 (predictive) DNA testing for CDKN2A (later complemented by 
CDK4) became available for members of melanoma families. 
The segments of the 2005 Dutch melanoma guidelines that cover the management of 
melanoma families, and that were in effect when this thesis was initiated, are presented in Box 1. 
As can be seen in box 1, the surveillance recommendations for FAMMM families in the 
2005 guidelines were similar for all families that fulfilled the criteria of at least two 
first-degree relatives or three melanomas in second-degree relatives. Surveillance recom-
mendations were independent of the presence or absence of a germline mutation in 
CDKN4/CDK4 in the family and family characteristics (e.g. the number of affected relatives). 
Given the fact that the chance of CDKN2A mutation detection was proven to be positively 
correlated with the number of melanoma patients in a family, it is anticipated that 
melanoma risk is higher in families with a high penetrance melanoma susceptibility 
gene-mutation (CDKN2A/CDK4) compared to CDKN2A/CDK4 wild-type families.22 In 
addition, it is expected that melanoma risk in families is positively correlated with the 
number of melanoma patients. There is a lack of prospective studies however that confirm 
these notions, and it is therewith unclear whether all melanoma families need to be 
surveillanced with the same scrutiny. 
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 Another point of discussion has been the necessity for second degree relatives to be 
under surveillance, as the yield of surveillance may be relatively small. Surveillance of 
second degree relatives has not been explicitly recommended in melanoma guidelines 
from other countries.57-59 In this thesis we present two studies that investigated melanoma 
detection rates in families with different CDKN2A mutation status and family characteristics 
(chapter 4) and in second degree relatives from CDKN2A mutated families (chapter 5).
‘Overdiagnosis’
A recurrent point of discussion related to melanoma surveillance is the issue of ‘misclassification’ 
of benign or indolent melanocytic proliferations as CMM. This point gained attention 
upon the observation that the incidence of melanoma has increased dramatically, while 
the mortality from melanoma has not increased proportionately. In addition, the increased 
melanoma incidence is disproportionally attributable to thin lesions.1,60 It has been argued 
that the ‘melanoma epidemic’ could (at least partially) be explained by increased public 
and physicians’ melanoma awareness and screening/surveillance, which resulted in three 
(overlapping) phenomena; 1. overdiagnosis, i.e. detection of indolent melanocytic tumors, 
that would either never progress or progress slowly enough that the patient dies of other 
Box 1   Guidelines with respect to the management of melanoma families from the 
Dutch Melanoma guidelines 2005 (appendix 3)13
Paragraph 3.1: Familial Dysplastic Nevus Syndrome (DNS)  
(= FAMMM syndrome = Familial Atypical Multiple Mole / Melanoma Syndrome)
Melanoma with/without dysplastic melanocytic nevi nevocellulares in at least two 
first-degree relatives or three melanomas in second-degree relatives.
Note: Presence of dysplastic melanocytic nevi increases the probability of being a
mutation carrier, but absence does not exclude being a carrier of the 
predisposition to melanoma.
Paragraph 5.2: 
Risk level 2 (greatly increased):
Being a members of a family (up to the second degree) with familial DNS / FAMMM 
syndrome (see section 3.1).
management:
• Information (oral and written)
• Once a year or more frequent skin examinations (absolute indication)
• Check children from the age of twelve years
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causes, and 2. diagnostic drift, i.e. classification of melanocytic lesions as CMM, that years 
ago would have been diagnosed as benign melanocytic lesions, and 3. increase in false 
positives as a result of submission of increasing numbers of equivocal melanocytic 
proliferations to the pathologist.60-62 Adversaries of this line of argumentation claim that, in 
stead, the epidemiological trends are mainly attributable to a real and steep increase in 
melanoma incidence due to behavioural changes regarding sun exposure. At the same 
time, mortality is believed to have been successfully constrained by strategies to advance 
melanoma diagnosis. The debate is ongoing.63 In chapter 6 we report an observation 
concerning the misclassification of melanocytic lesions as melanoma in the context of 
surveillance of CDKN2A mutated families.
Dermoscopy
Dermoscopy is a non-invasive technique in which oil immersion or polarised light are 
used to make the epidermis translucent and a lens is used for magnification to allow the 
visualization of structures not visible to the naked eye. Although the basic technique was 
already described in the late 19th century, it was not until the last two decades of the 20th 
century, after the introduction of handheld dermatoscopes, that dermoscopy gradually 
became integrated in the dermatological armamentarium.64, Dermoscopy is primarily 
used to supplement the clinical (naked eye) evaluation of (pigmented) skin lesions, that 
are suspicious of malignancy. The basic approach to these lesions consists of two steps: 
1. to distinguish melanocytic from non-melanocytic lesions, and 2. distinguish benign from 
malignant lesions. Several algorithms have been developed to facilitate a standardized 
assessment of (pigmented) lesions, including the pattern analysis, and more accessible 
simplified algorithms like the ABCD-method, Menzies method and seven point checklist.65-68 
The impact of dermoscopy on clinical practice
Numerous  studies have confirmed that dermoscopy improves the diagnostic accuracy 
for pigmented lesions.80-92 In 2008 a meta-analysis of dermoscopy studies performed in a 
clinical setting, reported a statistically significant better sensitivity for the diagnosis of 
melanoma for dermoscopy (0.90) compared to naked eye examination alone (0.71), 
without a significant difference in specificity (dermoscopy: 0.90, naked eye examination: 
0.81).69 Strikingly, the findings of the only randomized controlled study on dermoscopy in 
a dermatologist setting, presented a rather opposite view; a 42% reduction in patients 
referred to excision, without a change in sensitivity.70
 These contradictory findings may be related to the fact that the design of many 
dermoscopy studies possibly limited their applicability to clinical practice: clinicians 
judged (macro- and dermoscopic) images rather than life patients, study sets included 
only lesions that had been excised, and contained a disproportionate high number of 
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melanomas, dermoscopic images were not preceded by their accompanying macroscopic 
images, studies focussed on the impact of dermoscopy on the clinical (preferential) 
diagnosis, rather than management of lesions and many studies were performed in the 
setting of dermoscopy expert dermatologists. Performance of dermoscopy is likely to be 
highly dependent on the clinical context in which it is performed. As a consequence the 
actual impact of dermoscopy on the clinical dermatological practice is not fully clarified. 
In chapter 7 and chapter 8 we describe two studies in which we investigated the impact 
of dermoscopy on clinical practice both in general dermatology clinics as well as in the 
context of surveillance of melanoma families in an expert pigmented lesion clinic. These 
two clinic settings are expected to differ both in respect to the characteristics of the 
presented lesions (symptomatic lesions versus early asymptomatic lesions against the 
background of atypical nevi) as to the degree of dermoscopy expertise.
Aims and outline of the thesis
The general aims of this thesis are threefold. Firstly, we aimed to verify and substantiate 
the clinical and histological characteristic of melanoma (patients) from melanoma families 
with a pathogenic germline mutation in CDKN2A. Secondly, we aimed to investigate the 
effectiveness and yield of surveillance of melanoma families with different CDKN2A 
mutation status and family characteristics, and to identify possible causes for failure of 
surveillance. Thirdly, we aimed to investigate the impact of dermoscopy on the 
management of suspicious lesions in relatives from melanoma families under surveillance 
in a tertiary pigmented lesion clinic.
Chapter 2 investigates the clinical and histological characteristics of melanoma (patients) 
from families with a germline mutation in CDKN2A in comparison to sporadic melanoma 
(patients)
Chapter 3 investigates the effectiveness of surveillance by comparison of tumour 
thickness of surveillance detected cases with pre-surveillance detected cases in CDKN2A 
mutated families. Mode of detection and length of the surveillance interval are analyzed 
to identify possible causes for failure of surveillance.
Chapter 4 investigates the effectiveness of surveillance in families registered at the 
NFDHT. The yield of surveillance in families with different family characteristics- and 
CDKN2A mutation status was investigated by estimation of the melanoma detection rates.
Chapter 5 investigates the yield of surveillance of second degree relatives from families 
with a founder mutation in CDKN2A by estimating the melanoma detection rate and 
studying the family dynamics of two- to first-degree relative transitions.
Chapter 6 reports an observation related to the issue of ‘overdiagnosis’ in the context of 
surveillance of CDKN2A mutated families.
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Chapter 7 investigates the impact of dermoscopy on the preferential diagnosis and 
management decisions towards suspicious pigmented lesions in every day clinical 
practice of general dermatologists. This chapter is intended as a background for the 
findings reported in chapter 8.
Chapter 8 investigates the impact of dermoscopy on the preferential diagnosis and 
management decisions of suspicious pigmented lesions in high-risk patients from 
melanoma families.
Chapter 9 summarizes and discusses the findings described in the preceding chapters.
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Abstract
Background:
About 10% of cutaneous malignant melanomas (CMM) occur in individuals with a family 
history of melanoma. In 20% to 40% of melanoma families germline mutations in CDKN2A 
are detected. Knowledge of the clinicohistologic characteristics of melanomas and 
patients from these families is important for optimization of management strategies, and 
may shed more light on the complex interplay of genetic and environmental factors in the 
pathogenesis of melanoma. 
Objective:
We sought to investigate the clinical and histologic characteristics of CMM in CDKN2A- 
mutated families. 
Methods:
Clinical and histologic characteristics of 182 patients with 429 CMM from families with a 
founder mutation in CDKN2A (p16-Leiden mutation) were compared with 7512 patients 
with 7842 CMM from a population-based cancer registry. 
Results:
Patients with p16-Leiden had their first melanoma 15.3 years younger than control 
patients. The 5-year cumulative incidence of second primary CMM was 23.4% for patients 
with p16-Leiden compared with 2.3% for control patients. The risk of a second melanoma 
was twice as high for patients with p16-Leiden who had their first melanoma before age 
40 years, compared with older patients with p16-Leiden. Unlike control patients, there was 
no body site concordance of the first and second melanoma in patients with p16-Leiden 
and multiple primary melanomas. Patients with p16-Leiden had significantly more 
superficial spreading, and less nodular and lentiginous melanomas. 
Limitations: 
Ascertainment of patients with p16-Leiden was family based. The study was performed in 
families with a founder mutation, the p16-Leiden mutation. 
Conclusion:
Our findings are consistent with a pathogenic pathway of melanoma development from 
nevi, starting early and ongoing throughout life, and not related to chronic sun exposure. 
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Introduction
Between 6% and 14% of cases of primary cutaneous malignant melanoma (CMM) ) have 
been reported to occur in individuals with a family history of melanoma.1 In these families 
two major melanoma susceptibility genes have been identified so far. The oncogene 
CDK4 (MIM# 123829) has been found in a few melanoma families (estimated 2%).2 Germline 
mutations in CDKN2A (MIM# 600160) are far more prevalent and are found in approximately 
20% to 40% of melanoma families.3 CDKN2A encodes two distinct proteins: p16INK4 and 
p14ARF, which both function as tumor suppressors. The penetrance of CDKN2A mutations 
for melanoma has been estimated to be 0.67 by the age of 80 years.4 In The Netherlands 
the p16-Leiden mutation (c.225-243del19) is the most prevalent CDKN2A germline 
mutation.5 
Several studies have reported that patients with melanoma and a CDKN2A mutation have 
an earlier age of onset and have an increased risk of multiple primary melanomas (MPM).6-9 
The purpose of this study was to further substantiate and expand the knowledge of the 
clinical and histologic characteristics of patients with melanoma from CDKN2A-mutated 
families. Knowledge of these features may not only provide useful information for 
clinicians, but can also shed more light on the complex interplay of genetic and 
environmental factors in the pathogenesis of melanoma. 
We investigated the clinical and histologic characteristics of malignant melanoma in 
families with the p16-Leiden mutation, by comparing 182 patients with melanoma from 
p16-Leiden families who had 429 melanomas with patients and melanomas from a popu-
lation-based cancer registry. 
Methods 
P16-Leiden cases were collected from proven p16-Leiden-mutated families that were 
registered at The Netherlands Foundation for the Detection of Hereditary Tumors (NFDHT). 
The organization and methods of the NFDHT have been published elsewhere.10,11 In brief, 
physicians from all parts of The Netherlands refer families suspected for familial melanoma 
to the registry. Genealogic studies are performed and all reported malignancies are 
verified by medical records. If familial melanoma is confirmed clinically, the registry 
monitors the continuity of the surveillance program for relatives and collects follow-up 
data on the results of surveillance and pathologic examination. In 2007 the NFDHT 
database contained 51 p16-Leiden families with 194 patients with confirmed primary 
CMM since 1970. The majority of patients (n = 144, 74%) had been treated for at least one 
of their melanomas at the Department of Dermatology at the Leiden University Medical 
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Center, which is a tertiary referral center for familial melanoma. Most data on patient 
mutation status for the study were collected at this department as described elsewhere.12 
In addition we used results from clinical genetic testing, which the NFDHT receives if 
patients consent. 
Twelve melanoma patients that had tested negative for the p16-Leiden mutation in their 
family were excluded from the study. The remaining 182 patients consisted of 127 proven 
mutation carriers and 55 untested patients (from proven p16-Leiden families). As 8.6% 
(12/139) of gene-tested patients tested negative for the p16-Leiden mutation, we expected 
about 5 phenocopies among the 55 untested patients. We found this acceptable and 
decided to include the untested patients as p16-Leiden patients in the study. For each 
patient, follow-up data were collected on subsequent melanomas and life status. 
 Control patients were obtained from the Leiden Cancer Registry (LCR). The LCR is a 
population-based registry of all newly diagnosed malignancies, which covers the western 
part of The Netherlands with a population of approximately 1.7 million inhabitants. The 
registry has (near) complete coverage since 1989. For new patients in the registry, 
malignancies diagnosed before the start of the registry are also recorded. All patients with 
histologically confirmed primary cutaneous melanoma up to September 2007 were 
selected from the cancer registry. The patients known to be members of p16-Leiden 
families were excluded from the LCR database. Survival data of the control patients were 
obtained from the Central Bureau for Genealogy and from the municipal registries, which 
keep records of all deceased persons in The Netherlands. Survival data were completed 
until January 2006. The LCR contained a total of 7512 eligible patients. For control patients 
no data on CDKN2A mutation status were available. For all included patients, data were 
gathered concerning date of birth and gender. For all melanomas, data were collected 
concerning date of diagnosis, histologic type, and body site. 
Statistical analyses 
Body site was subdivided into head and neck, trunk, upper extremities, lower extremities, 
and not recorded. Histologic type was categorized as superficial spreading melanoma 
(SSM) or melanoma in situ (Mis), nodular melanoma (NM), lentigo maligna (LM) melanoma 
(LMM) or LM, and acral lentiginous melanoma (ALM) or ALM in situ. Other histologic types 
and melanomas that were not otherwise specified were excluded from all analyses that 
included the variable histologic type. In some analyses a dichotomous covariate was 
included to distinguish invasive from in situ melanomas. Age and year of diagnosis were 
analyzed as continuous variables. In some analyses age was divided in two categories. To 
distinguish the two study populations we used the term “p16-Leiden status”, coded 1 for 
patients with p16-Leiden, and 0 for control patients. This term refers to being a member of 
a p16-Leiden-mutated family, rather than personal mutation status (see above).
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Differences in gender distribution and age at diagnosis were calculated with the Pearson 
x2 and Student t test, respectively. The cumulative incidence of second primary melanomas 
was calculated using a competing risk analysis13 accounting for death as competing risk. 
Survival times were calculated from the date of first melanoma to the date of second 
melanoma, death, or last follow-up. For control patients, January 2006 was considered as the 
end of follow-up as data on life status were only available until this date. Melanomas 
diagnosed after January 2006 were therefore excluded from the competing risk analyses. 
A Cox proportional hazard model was used to compare the hazard of developing a 
second primary melanoma in the two study populations, and to study risk factors for 
developing a second melanoma in the two populations separately. Because the risk of 
developing a second melanoma was age dependent in both populations, separate hazard 
ratios (HRs) were calculated for age below and above 40 years. Equality of HRs across age 
groups was tested using Cox regression with p16-Leiden status, age group, and their 
interaction. To identify risk factors for a second primary melanoma, the following covariates 
were tested in univariate analyses: age of diagnosis (<40 vs >40 years), age of diagnosis 
(<60 vs >60 years), gender, year of diagnosis, tumor type (SSM/Mis, NM, LMM/LM, ALM/
ALM in situ), tumor localization (lower extremities, head/neck, trunk, upper extremities), 
and invasiveness of the first melanoma (in situ vs invasive melanoma). Covariates with a P 
value less than .10 in the univariate analyses were included in the multivariate analyses. 
Body site concordance of the first and second primary melanoma was calculated with 
Cohen k statistics. To compare concordance in patients with p16-Leiden and control 
patients an analysis of variance was performed. 
For comparison of tumor characteristics of p16-Leiden cases and control patients, a 
multivariate logistic regression analysis was performed with robust SEs to correct for 
within-patient correlations in relatives with MPM. Comparison of the age at diagnosis 
according to body site pattern in the two study populations was done by means of a 
3-way analysis of variance. 
 All analyses were performed with software (SPSS 14.0, SPSS Inc, Chicago, IL, and R 
2.5.1, R Development Core Team, Vienna, Austria). Statistical significance was determined 
at a = .05, and all tests for statistical significance were two-sided. 
Results 
Patient characteristics 
In total 182 patients with p16-Leiden melanoma and 429 CMM, and 7512 control patients 
with melanoma and 7842 CMM were included in the analyses. Patient characteristics are 
presented in Table 1. The gender distribution was similar in both groups. Age at diagnosis 
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(n = 182) (n = 7512)
p16-Leiden mutation status
   Positive 127 (69.8%) N/A
   Not tested 55 (30.2%) N/A
Gender
   Male 80 (44.0%) 2977 (39.6%) 0.24
   Female 102 (56.0%) 4535 (60.4%)
Age
   Mean (SD), Male 40.5 yrs (13.0) 55.3 yrs (16.7) < 0.001
   Mean (SD), Female 37.9 yrs (13.5) 53.7 yrs (18.0) < 0.001
   Mean (SD), All 39.0 yrs (13.3) 54.3 yrs (17.5) < 0.001
Total No. of melanomas 429 7842
No. of melanomas / patient
   1 108 (59.3%) 7239 (96.4%) < 0.001
   2 30 (16.5%) 236 (3.1 %)
   3-5 27 (14.8%) 34 (0.5%)
   > 5 17 (9.3%) 3 (0%)
Cum. Incidence of second  
melanoma
   1-Year incidence 8.5% 1.0%
   2-Year incidence 12.2% 1.5%
   5-Year incidence 23.4% 2.3%
   10-Year incidence 34.8% 3.1%
   20-year incidence 41.4% 4.5%
Tumor type < 0.001
   SSM/Mis 338 (88.9%) 4205 (66.2%)
   NM 29 (7.6%) 1129 (17.8%)
   LMM/LM 8 (2.1%) 973 (15.3%)
   ALM/ALMis 5 (1.3%) 47 (0.7%)
   Other 1 275
   NOS 48 1213
Location < 0.001
    Male
      Head & Neck 27 (14.4%) 720 (23.4%)
      Trunk 102 (54.3%) 1396 (45.4%)
      Upper extremities 26 (13.8%) 486 (15.8%)
      Lower extremities 33 (17.6%) 473 (15.4%)
      Unknown 1 38
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(of the first melanoma) was significantly younger in patients with p16-Leiden (mean: 39.0 
years) compared with the control patients (mean: 54.3 years). The mean age difference 
was 15.3 years (95% confidence interval [CI] 13.3-17.3). In both populations women had 
their first melanoma at a slightly younger age than men, but the difference was only 
statistically significant in the control population (control: P <.001; p16-Leiden: P = .189). 
Multiple primary melanomas 
Patients with p16-Leiden were followed up for a median of 10.4 years (range 0-35.7), and 
control patients for 5.5 years (range 0-36.0). MPM developed in 40.7% of the patients with 
p16-Leiden and 3.6% of the control patients. Patients with p16-Leiden and MPM had more 
primary CMM per patient than control patients with MPM (median: 3.0 [range 2-19] vs 2.0 
[range 2-10]).
The estimated 5-year cumulative incidence of a second primary tumor was 23.4% for 
patients with p16-Leiden and 2.3% for control patients (Table I). Patients with p16-Leiden 
were at a considerably higher risk of a second CMM than control patients (Fig 1). The HR 
was dependent on the age of diagnosis of the first melanoma, with a HR of 15.8 (95% CI 
11.0-22.7, P < .001) for age younger than 40 years, and a HR of 7.5 (95% CI 4.5-12.7, P < .001) 
for age older than 40 years. These HRs were significantly different (P value for p16-Leiden 
status by age group interaction = .016). 






(n = 182) (n = 7512)
    Female
      Head & Neck 26 (10.9%) 828 (17.8%)
      Trunk 70 (29.4%) 1186 (25.4%)
      Upper extremities 45 (18.9%) 963 (20.7%)
      Lower extremities 97 (40.8%) 1684 (36.1%)
      Unknown 2 68
Invasiveness
   In situ 94 (22.0%) 1641 (20.9%) 0.61
   Invasive 334 (78.0%) 6201 (79.1%)
   Unknown 1
N/A, not applicable; SD, standard deviation; MPM-patients, multiple primary melanoma patient; Cum. incidence, 
cumulative incidence; SSM/Mis, Superficial Spreading Melanoma or Melanoma in situ; NM, Nodular Melanoma; 
LMM/LM, Lentigo Maligna Melanoma or Lentigo Maligna; ALM/ALMis, Acrolentiginous Melanoma or Acrolen-
tiginous Melanoma in situ; NOS, not otherwise specified
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Risk factors for multiple melanomas 
For patients with p16-Leiden, diagnosis of a melanoma before age 40 years was a 
significant risk factor for the development of a second CMM (HR 1.9, 95% CI 1.2-3.2, P = .011). 
For control patients localization of the first melanoma in the head and neck region was a 
statistically significant risk factor for a second CMM (HR 1.61, 95% CI 1.04-2.50, P = .032, 
“lower extremities” as reference category). 
Body site concordance 
The overall concordance of body site of the first and second melanoma was 36.1% for 
patients with p16-Leiden MPM (κ statistics 0.08, SE = 0.071, P = .250) and 52.5% for control 
patients with MPM (k statistics 0.36, SE = 0.041, P < .001). The difference in body site 
Figure 1   Cumulative incidences of second melanomas with 95% confidence 
intervals in the p16-Leiden (upper line) and control (lower line) population
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concordance between the two populations was statistically significant (P < .001). In the 
control population concordance was dominated by melanomas in the head and neck 
region (73.7%) (Table 2). 
Tumor body site and histologic type 
A multivariate analysis was performed to investigate differences between p16-Leiden 
cases and controls concerning tumor type and tumor localization, while adjusting for age 
of diagnosis, gender, incidence year, and invasiveness. A statistically significant difference 
in tumor type distribution was found. Patients with p16-Leiden had a smaller proportion 
of NM (odds ratio 0.38) and LMM/LM (odds ratio 0.20) than control patients (Table 3). There 
was no difference in tumor localization between patients with p16-Leiden and control 
patients. 
Age at diagnosis related to body site 
Patients with p16-Leiden developed melanomas on the head and neck and lower 
extremities at a younger age than melanomas on the trunk and upper extremities (Table 4). 
In the control patients head and neck tumors were diagnosed at an older age than tumors 
on all other body sites. The difference between age at diagnosis by body site pattern of 
patients with p16-Leiden and control patients was statistically significant (P < .001). 
Table 2   Concordance of body site for first and second primary cutaneous melanoma 









































































































MPM, Multiple Primary Melanomas; H&N, Head and neck; T, Trunk; UE, Upper Extremities; LE, Lower Extremities
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Table 3   Multivariate analysis for characteristics associated with p16-Leiden families
Covariate OR (95% CI) p-value
Age 0.96 (0.95 – 0.97 ) < 0.001
Gender
   Male 1
   Female 0.70 (0.43 – 1.13) 0.14
Incidence year 0. 91 (0.89 – 0.94) < 0.001
Invasiveness
   In situ 1
   Invasive 0.74 (0.54 – 1.01) 0.067
Tumor type
   SSM/Mis 1
   NM 0.38 0.25 – 0.57) < 0.001
   LMM/LM 0.20 (0.10 – 0.40) < 0.001
   ALM/ALMis 0.96 (0.38 – 2.44) 0.93
Localization 
   Lower extremities 1
   Head/neck 1.35 (0.84 – 2.16) 0.22
   Trunk 1.07 (0.79 – 1.43) 0.68
   Upper extremities 1.07 (0.77 – 1.49) 0.67
OR, Odds ratio; 95% CI, 95% confidence interval; SSM/Mis, Superficial Spreading Melanoma or Melanoma in situ; 
NM, Nodular Melanoma; LMM/LM, Lentigo Maligna Melanoma or Lentigo Maligna; ALM/ALMis, Acrolentiginous 
Melanoma or Acrolentiginous Melanoma in situ
Control patients are the reference population. 
Table 4   mean age at diagnosis for different tumor localizations in p16-Leiden and 
control patients
p16-Leiden patients Control patients
Localization Age* (SD) n Age* (SD) n
Trunk 41.5 yrs (11.8 yrs) 72 50.0 yrs (15.5 yrs) 2495
Head/neck 36.1 yrs (14.6 yrs) 24 65.4 yrs (16.8 yrs) 1447
Upper extremities 41.6 yrs (13.9 yrs) 27 55.0 yrs (17.0 yrs) 1379
Lower extremities 36.3 yrs (13.7 yrs) 57 51.4 yrs (17.4 yrs) 2086
Unspecified 25.3 yrs (14.5 yrs) 2 52.4 yrs (16.6 yrs) 105
Total 39.0 yrs (13.3 yrs) 182 54.3 yrs (17.5 yrs) 7512
*For multiple melanoma patients the age at diagnosis of the first melanoma was taken. SD, standard deviation
Characteristics of melanoma in families with a CDKN2A mutation | 37
Because patients with p16-Leiden had considerably less LMM/LM, which are known to be 
diagnosed at an older age and frequently occur in the head and neck region, we 
performed a subanalysis in which we excluded all LMM/LM. The difference in age by body 
site patterns remained highly statistically significant in this analysis (P < .001). 
Discussion 
We compared the clinical and histologic characteristics of 182 patients with 429 CMM 
from families with a germline mutation in CDKN2A, with a large control population from 
the Leiden population-based cancer registry (7512 patients with 7842 CMM). Patients with 
p16-Leiden melanoma had a younger age of onset and a highly increased risk of MPM, 
which was highest for patients who had their first melanoma before the age of 40 years. 
In contrast to control patients with MPM no body site concordance was found for first and 
second melanomas in patients with p16-Leiden MPM. Patients with p16-Leiden had a 
higher proportion of SSM/Mis and less NM and LMM/LM. Furthermore, a different age (at 
diagnosis) by body site pattern was found in the two populations.
The patients with p16-Leiden had a considerably younger age of onset of 39 years. Other 
studies reported a comparable age at diagnosis for CDKN2A mutation carriers, ranging 
from 36.3 to 43.3 years.7-9 
 With regard to the occurrence of MPM in patients with p16-Leiden our findings are in 
accordance with earlier reports, and contain some new observations. Like previous studies 
on CDKN2A-mutated families, we found a very high proportion of patients with MPM 
(40.7%) in the p16-Leiden population. It was strikingly higher than the 18.6%8 and 25.6%6 
of patients with MPM reported in two other studies. The results are difficult to compare, 
however, because the duration of follow-up was not recorded in these studies. We 
estimated the 5-year cumulative incidence of second melanomas to be 23.4% in the 
p16-Leiden population, and 2.3% in the control population, which was similar to the 1.5% 
to 3.4% reported in other population-based studies.14-16 In a clinic-based study, Ferrone et 
al17 found a 5-year risk of 11.4%. This relatively high risk may have been because of the fact 
that their study was performed in a tertiary cancer center. Diagnosis of the first melanoma 
at a young age (<40 years) was associated with an almost doubled risk of MPM in the 
p16-Leiden population. 
 Unlike patients with p16-Leiden MPM, there was a statistically significant association 
between the body site of the first and second melanoma in control patients with MPM. In 
the control population overall body site concordance was 53%, which was similar to the 
48% to 55% reported in earlier studies in comparable populations.17-19 Like Giles et al,18 we 
found concordance to be highest for tumors located in the head and neck area. The 
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absence of body site concordance in patients with p16-Leiden melanoma, in addition to 
the highly increased risk of MPM, underlines the importance of frequent and lifelong 
total-body skin examinations for these patients. 
Patients with p16-Leiden had proportionally less NM and LMM/LM, but more SSM/Mis 
than control patients. There are earlier reports of a decreased proportion of NM in familial 
melanoma.20 LMM/LM are diagnosed in extensively sun-damaged skin, usually in elderly 
people. Because patients with p16-Leiden had a much younger age of onset, less LMM/
LM were expected in this patient population. But even though we adjusted for age, the 
difference remained strongly significant. An increased proportion of superficial spreading 
type melanomas in familial melanoma has been reported before.21 It has been suggested 
that this is because a relatively large proportion of melanomas in patients with familial 
melanoma arises from (dysplastic) nevi as familial melanoma is associated with increased 
numbers of (dysplastic) nevi. Melanomas that are associated with nevi are usually of the 
superficial spreading type.22 In a recent study Nagore et al23 observed no acral melanomas 
among 41 familial melanoma cases. In our study the proportion of ALM/ALM in situ 
melanomas was similar in patients with p16-Leiden and control patients. The absence 
reported by Nagore et al23 may be a result of small sample size in their study. 
In accordance with previous studies,24,25 we found that in the control population, head and 
neck melanomas were diagnosed at a considerably older age than melanomas on other 
body sites. Interestingly in the p16-Leiden population head and neck tumors were 
diagnosed at a younger age than tumors located on the trunk and upper extremities, 
even after exclusion of LMM/LM from the analysis. 
Our findings in the p16-Leiden population are in accordance with the inherited increased 
susceptibility to melanoma that CDKN2A germline mutations are associated with, 
including the: (1) young age of onset; (2) high risk of MPM; and (3) absence of body site 
concordance of the first and second melanoma in patients with MPM. Besides this, our 
results also suggest that differences exist between the pathogen„esis of melanomas in 
patients with p16-Leiden and control patients. Several studies have brought forward that 
melanoma is a heterogeneous 
disease.24,26-28 Whiteman et al27,28 proposed two distinct etiologic pathways, one associated 
with increased numbers of nevi, intermittent sun exposure, younger age at diagnosis, and 
location on the trunk (nevus pathway). The second pathway is associated with chronic sun 
exposure, fewer nevi, older age at diagnosis, and location in the head and neck region 
(ultraviolet B pathway). Our results in the control population are in accordance with this 
theory, as both pathways can be distinguished in this population. First of all, age at 
diagnosis was considerably higher for tumors in the head and neck region compared with 
tumors on the trunk, which is in support of the theory of a different origin for these two 
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body sites. Secondly, we found a statistically significant body site concordance in patients 
with MPM, with a high concordance for head and neck tumors. This clustering suggests a 
localized increased melanoma risk, which is in agreement with the divergent pathway 
theory. In the p16-Leiden population, the high proportion of superficial spreading type 
melanomas and lack of lentiginous melanomas suggest that melanomas in these patients 
develop predominantly through the nevus pathway. The young age at diagnosis of 
melanomas located in the head and neck region is difficult to interpret, however. Relatively 
high ultraviolet exposure at this body site might play a roll (synergy of the nevus and 
ultraviolet B pathways). 
The ascertainment of patients with p16-Leiden was family based, which is a possible 
source of bias. Familial melanoma with a young age of onset or MPM are more likely to be 
identified and genetically tested. The differences between the p16-Leiden population and 
control population would probably have been smaller if patients with p16-Leiden had 
been ascertained from a patient population unselected for family history. Such a design 
has serious drawbacks, however, given the low prevalence of CDKN2A mutations in 
patients with general melanoma (0.2%-2.0%).29,30 Moreover, we consider our results to be 
representative for patients from proven p16-Leiden families, as they present in clinic in 
daily practice. 
In summary, we have verified and substantiated several characteristics of patients with 
familial melanoma and a CDKN2A mutation in a large case-control study and we have 
reported a number of new findings. Our findings are in concordance with the so-called 
divergent pathways hypotheses: familial melanomas tend to follow the nevus pathway. 
More studies are necessary to determine whether our results apply to founder populations 
with other CDKN2A mutations as well. 
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Abstract
Background: 
For more than 25 years families with an increased susceptibility to melanoma have been 
under surveillance at our institution. 
Objective: 
We sought to investigate the effectiveness of surveillance for CDKN2A-mutated families 
and causes for failure of the program in patients with more advanced tumors. 
Methods:
In a retrospective case-control study, Breslow thickness of melanomas diagnosed in relatives 
enrolled in the surveillance program were compared with melanomas of unscreened 
index patients. We investigated the influence of mode of detection and length of 
surveillance interval on outcome. 
Results: 
Surveillance melanomas (n = 226, median thickness: 0.50 mm) had a significantly lower 
Breslow thickness (multiplication factor: 0.61 [95% confidence interval 0.47-0.80], P \ .001) 
than index melanomas (n = 40, median thickness: 0.98 mm). Index melanomas were more 
likely diagnosed with a Breslow thickness greater than 1.0 mm (odds ratio: 3.1 [95% 
confidence interval 1.2-8.1], P = .022). In all, 53% of surveillance melanomas were diagnosed 
during regular screens, 7% during patients’ first screen, 20% between regular screens, and 
20% in patients who were noncompliant with the surveillance schedule. The majority of 
surveillance melanomas (58%) were detected within 6 months after the last screen. There 
was no correlation between tumor thickness and the length of the screening interval for 
tumors diagnosed within 24 months since the last screen. 
Limitations:
The study is retrospective. 
Conclusions:
Surveillance was associated with earlier detection of melanomas. Noncompliance was an 
important cause for failing surveillance. Shortening surveillance intervals may advance 
detection of tumors, but may paradoxically have little impact on prognosis.
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Introduction
About 10% of primary cutaneous malignant melanomas have been reported to occur in 
families.1 In 1994, germline mutations in the CDKN2A gene (MIM# 600160) were 
demonstrated in kindreds with hereditary melanoma.2,3 CDKN2A encodes two distinct 
proteins: p16INK4 and p14ARF, both of which function as tumor suppressors. CDKN2A is 
the most prevalent high-penetrance melanoma susceptibility gene, mutations being 
detected in the germline in 20% to 40% of melanoma families.4-6 Mutations in CDKN2A 
have an estimated penetrance of 67% by the age of 80 years.4 
In 1981 the familial melanoma study group of the Leiden University Medical Center (LUMC) 
initiated a surveillance program for familial melanoma kindreds. Many of the first families 
that were screened at the LUMC were later shown to have a founder mutation in CDKN2A, 
consisting of a 19 base pair deletion in exon 2 (the p16-Leiden mutation).7 
In 1989 we evaluated the surveillance program for these families, and reported that 
screen-detected melanomas (n = 31) had more favorable prognostic characteristics than 
those detected before the start of the surveillance program (n = 19).8 We have noticed, 
however, that in spite of the surveillance program, some melanomas are detected 
relatively late. Possible explanations include: noncompliance with follow-up instructions; 
intervals between screens being too long to warrant early detection in all instances, 
because some melanomas grow rapidly9; failure to recognize melanomas because of an 
atypical clinical presentation10; or inadequate screening. 
 In the current study we compared the Breslow thickness of 226 melanomas of 
patients from p16-Leiden mutation positive families who were enrolled in the surveillance 
program with 40 melanomas of index patients from the same families, diagnosed before 
recognition of heredity for melanoma in these families. In addition we looked at the 
length of the surveillance intervals and the mode of detection of the melanomas. 
Methods
The majority of families under surveillance at the LUMC were ascertained through the 
pigmented lesions clinic of the department of dermatology from 1980 onward. Family 
trees have been constructed for each kindred, initially at the clinic and later at The 
Netherlands Foundation for the Detection of Hereditary Tumors. Ascertainment of family 
data at the clinic11 and The Netherlands Foundation for the Detection of Hereditary 
Tumors8,12 has been described in detail elsewhere. Family members of clinically proven 
melanoma pedigrees were invited to the surveillance program, which consisted of an 
annual total skin examination. If a melanoma was diagnosed, surveillance was intensified 
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during the first 5 years after diagnosis (every 3 months during the first year, every 4 months 
during the second year, and every 6 months during the third to fifth year). 
 Before and after the identification of the p16-Leiden mutation in 1994, blood samples 
for research purposes have been collected from relatives who signed an informed consent 
form. Pedigree information was updated on a regular basis. We consider cancer data for all 
included families to be complete from 1970 onward. All melanomas diagnosed in family 
members who had been enrolled in the LUMC surveillance program were selected. These 
included tumors detected at the pigmented lesions clinic of the LUMC, and melanomas 
incidentally detected at other departments and by general practitioners. Melanomas 
detected before the start of the surveillance program in relatives who were under 
surveillance because of previous melanomas were also included. They were all termed 
“surveillance melanomas.” Melanomas diagnosed in patients who had continued their 
surveillance at another institution were excluded. The first melanoma of the first two 
patients with melanoma from each family served as controls. They were detected before 
recognition of heredity for melanoma in these families, and termed “index melanomas.” 
In total, 344 melanomas diagnosed in relatives from 37 families were eligible to the study. 
For each patient, data were collected concerning date of birth and gender. For all melanomas, 
data on Breslow thickness, histologic type, and date of diagnosis were gathered and 
patient age at time of diagnosis was calculated. Screening intervals were calculated as the 
time between the last screen and melanoma detection. All tumors with missing data 
on Breslow thickness or histologic type, all in situ melanomas, and melanomas other than 
the superficial spreading histologic type (n = 132) were reviewed by one of us (W. J. M.). 
In all, 28 lesions were excluded from the study, because they were reclassified as benign 
(n = 22), unclassifiable (n = 5), or recurrent melanoma (n = 1). In situ melanomas and 
invasive melanomas with missing data on Breslow thickness that were unavailable for 
revision were excluded from the study. 
We distinguished 4 modes of detection after enrollment in the surveillance program and 
surveillance melanomas were classified accordingly. Melanomas diagnosed at the first 
screen were termed “first-screen melanomas.” If melanomas were detected at a subsequent 
screen, they were termed “regular-screen melanomas.” Tumors that were detected between 
scheduled screens were termed “interval melanomas.” The final category, “noncompliance 
melanomas,” consisted of melanomas that were detected more than 2 months after the 
recommended screening interval. The margin of 2 months was taken because there have 
been waiting lists for the pigmented lesions clinic in the past (Fig 1). 
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Statistical analysis 
Multivariate linear regression and binary logistic regression analyses were performed to 
calculate the effect of surveillance on Breslow thickness. Comparisons were made between 
surveillance melanomas and index melanomas, and among the 4 surveillance melanoma 
categories and index melanomas. In the linear regression analyses a log- transformed 
Breslow thickness was used. Because differences in the log-transformed variable translate 
to multiplication factors on the original scale, results are reported as multiplication factors 
on the original scale. In the logistic regression analyses Breslow thickness was analyzed as 
a categorical variable, coded 1 for Breslow thickness less than or equal to 1.00 mm, and 2 
for greater than 1.00 mm. All analyses were adjusted for gender, age at diagnosis (in years), 
and year of diagnosis. 
 Many patients had multiple primary melanomas. We anticipated that these patients 
had their subsequent melanomas diagnosed at a more favorable prognostic stage than 
their first melanoma, not just because of surveillance, but also because of a change of the 
patients’ and physicians’ attitudes and behavior because of the previous (first) melanoma. 
For this reason we adjusted for melanoma rank, using a covariate coded 1 for first 
melanoma and 2 for all subsequent melanomas. In addition we used generalized 
estimating equations13 to correct for within-patient correlations; this method uses 
sandwich estimators to calculate robust SEs. Correlation between the length of the 
screening interval and tumor thickness was calculated with linear regression analyses, 
with log-transformed Breslow thickness as dependent and the screening interval (in years) 
as covariate. 
 All analyses were performed with software (SPSS 14.0, SPSS Inc, Chicago, IL, and R 
2.5.1, R Development Core Team, Vienna, Austria). The package geepack14 was used for the 
calculation of adjusted SEs. Statistical significance was determined at a = .05, and all tests 
were two-sided. For analyses in which more than two groups were compared a Bonferroni 
correction for multiple testing was performed. 
Figure 1   Screening categories according to mode of ascertainment
Bold vertical lines = scheduled screening appointment; dashed vertical line = skipped screening appointment. 
Arrows indicate moment of diagnosis, and accompanying numbers refer to screening category: 1 = first-screen 




48 | Chapter 3
Results
In total, 266 melanomas from 114 patients were included (Table 1). These melanomas 
consisted of 40 index melanomas and 226 surveillance melanomas. Median Breslow 
thickness was 0.98 mm for index melanomas and 0.50 mm for surveillance melanomas 
(Table II). The mean thickness of surveillance melanomas was 0.61 times that of index 
melanomas (95% confidence interval [CI] 0.47-0.80, P < .001). The probability of being 
diagnosed with a Breslow thickness greater than 1.00 mm was significantly larger for index 
melanomas (odds ratio [OR] 3.1, CI 1.2-8.1, P = .022). 
Mode of detection of surveillance melanomas 
Classification according to mode of detection was possible for 191 surveillance melanomas 
(85%) (Table 2). Tumors were classified as follows: 13 first-screen (7%), 102 regular-screen 
(53%), 38 interval (20%), and 38 noncompliance (20%) melanomas. Compliance was related 
to the number of melanomas for which patients had previously been given a diagnosis. 
The proportion of noncompliance melanomas was 46% among first melanomas, and 26% 
of first melanomas were regular-screen melanomas. For subsequent melanomas, patient 
compliance steadily increased (Table 2). 
Screening interval 
Most regular-screen (72%) and interval (68%) melanomas were diagnosed in patients who 
were under intensified surveillance because of a previous melanoma. The median interval 
between the last screen and moment of detection was 5 months for regular-screen 
melanomas, 3.5 months for interval melanomas, and 24 months for noncompliance 
Table 1   Patient characteristics
Patients (n = 114)
Gender
   Male 50 (44%)
   Female 64 (56%)
No. of melanomas / patient
   1 61 (54%)
   2 22 (19%)
   3-5 19 (17%)
   6-10 8 (7%)
   > 10 4 (4%)
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melanomas (Table2). The Breslow thickness of surveillance melanomas was not correlated 
with the length of the screening interval for intervals less than 24 months (Table 3) (linear 
regression analysis, multiplication factor: 1.01/y, 95% CI 0.83-1.23, P = .917). If melanomas 
detected after an interval of more than 24 months were included in the analysis a 
significant correlation between screening interval and Breslow thickness was found 
(multiplication factor: 1.09/y, 95% CI 1.03-1.15, P = .003). 
Detection of interval melanomas 
Most interval melanomas (n = 21, 55%) were detected by patients themselves, with a 
median Breslow thickness of 0.55 mm (range: in situ-1.60 mm), after a median interval of 5 
months (range: 1 - 11). Ten interval melanomas (26%) were diagnosed by physicians at an 
appointment for the excision of another pigmented lesion, judged to be suspicious at the 
last screen (median thickness: 0.40 mm [in situ - 0.90 mm], interval: 1 month [0-2]). 
Physicians consulted for another medical condition diagnosed 6 of the interval melanomas 
(16%, median thickness: 0.38 mm [in situ-3.90 mm], interval: 7.5 months [2-11]). One interval 
melanoma was detected in a research project (thickness: 2.00 mm, interval 3 months). 
Tumor thickness according to mode of detection 
The tumor thickness according to mode of detection is shown in Table 4. Regular-screen 
melanomas were significantly thinner than index melanomas (multiplication factor: 0.53, 
95% CI 0.46-0.87, P <.001) and at borderline significance, first-screen melanomas were 
thinner than index melanomas (multiplication factor: 0.63, 95% CI 0.46-0.87, P = .0053, 
significance at a = .005, because of multiple testing) (Table 5). The probability of diagnosing 
Table 3   Tumor thickness according to the time interval between the last screening and 
the moment of melanoma diagnosis
Time Interval n Median* (range) n Mean** (SD)
0 – 4 months 69 0.48 (Mis – 2.10) 57 0.62 (0.39)
5 – 8 months 43 0.55 (Mis – 3.90) 36 0.70 (0.64)
9 – 12 months 27 0.50 (Mis – 1.40) 23 0.53 (0.25)
13 – 18 months 11 0.50 (Mis – 1.20) 8 0.68 (0.27)
19 – 24 months 10 0.49 (Mis – 1.00) 8 0.61 (0.28)
> 24 months 17 0.48 (Mis – 2.60) 13 1.07 (0.77)
Total 177*** 0.50 (Mis – 3.90) 145 0.67 (0.49)
Mis, melanoma in situ.
* Based on in situ and invasive melanomas; 95% CI, 95% confidence interval.
** Based on invasive melanomas only; SD, standard deviation.
*** One missing value for a noncompliance melanoma.
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a tumor with Breslow thickness greater than 1.00 mm was not significantly different 
between any of the screening categories and index melanomas (Table 5). 
 To further investigate possible differences between the different screening categories 
we performed a subanalysis with a cut-off point of 0.75 mm, as used in older versions of 
the American Joint Committee on Cancer staging system. The probability of being 
diagnosed with a tumor thickness greater than 0.75 mm was significantly larger for index 
melanomas than for regular-screen melanomas (OR 14.6, CI 4.4-48.2, P < .001) (Table 5), 
interval melanomas (OR 7.7, CI 2.0-29.3, P = .0029), and first-screen melanomas (OR 6.6, 95% 
CI 1.8-24.4, P = .0047). Noncompliance melanomas had a higher probability of being 
diagnosed with a Breslow thickness greater than 0.75 mm than regular-screen melanomas 
(OR 4.8, CI 1.8-13.2, P = .0021). 
Table 4   Cumulative number and proportion of cases according to Breslow thickness
Breslow thickness
Category Mis ≤ 0.75mm ≤ 1.00mm ≤ 2.00mm ≤ 4.00mm Total
Index: 0 (0%) 13 (33%) 23 (58%) 32 (80%) 38 (95%) 40
Surveillance:
-  First screening 0 (0%) 10 (77%) 11 (85%) 13 (100%) - 13
-  Regular screening 17 (17%) 88 (86%) 96 (94%) 101 (99%) 102 (100%) 102
-  Interval 8 (21%) 30 (79%) 33 (87%) 37 (97%) 38 (100%) 38
-  Noncompliance 7 (18%) 24 (63%) 31 (82%) 36 (95%) 38 (100%) 38
-  Not categorized 3 (9%) 29 (83%) 30 (86%) 33 (94%) 35 (100%) 35
Surveillance (all): 35 (16%) 181 (80%) 201 (89%) 220 (97%) 226 (100%) 226
Mis, melanoma in situ
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Discussion
We evaluated the effectiveness of our surveillance program for familial melanoma kindred 
with the p16-Leiden mutation in CDKN2A. The tumor thickness of 226 melanomas of 
relatives enrolled in the surveillance program was compared with 40 melanomas 
diagnosed in index patients. 
 Surveillance melanomas were significantly thinner than index melanomas, indicating 
that melanomas were detected in an earlier stage during the surveillance program. This is 
to some degree surprising, given the fact that only 53% of the surveillance melanomas 
were detected at a regular screen. Of surveillance melanomas, 7% were detected at first 
screens, 20% between regular screens, and 20% in patients who were not compliant with 
follow-up instructions at the time of diagnosis. Mode of ascertainment clearly influenced 
the effectiveness of surveillance. Only first-screen and regular-screen melanomas had a 
significantly lower Breslow thickness than index melanomas. There were no significant 
differences in the probability of being diagnosed with a tumor thickness greater than 1.00 
mm among melanomas of any of the 4 surveillance melanoma categories and index 
melanomas. It is likely that this was caused by lack of statistical power, as significance was 
determined at a = .005 because of multiple testing. In a subanalysis with a cut-off point of 
0.75 mm, all surveillance melanoma categories except for noncompliance melanomas 
were associated with a significantly smaller probability of being diagnosed with a tumor 
thickness greater than 0.75 mm compared with index melanomas. 
 The mean tumor thickness of regular-screen melanomas (0.58 mm) was comparable 
with those of screen-detected melanomas reported in other studies (0.52-0.56 mm).8,15,16 
Hansson et al17 reported that 93% of 41 melanomas detected in the Swedish national 
preventive program for melanoma kindred had a tumor thickness less than 1.00 mm, 
which was comparable to the 89% in our study. These other studies did not specify, 
however, whether interval melanomas and melanomas in noncompliant patients were 
included. 
 First-screen melanomas had a higher mean tumor thickness than regular-screen 
melanomas, but the difference was not statistically significant. First-screen melanomas 
did have a significantly lower Breslow thickness than index melanomas, however. These 
findings are in accordance with earlier studies.8,15,16 
As much as one fifth of melanomas were diagnosed in patients who were not compliant 
with follow-up instructions at the time of diagnosis. Moreover, almost half of patients 
were noncompliant at the time of diagnosis of their first melanoma. Noncompliance had 
a negative impact on melanoma detection as the probability of being diagnosed with a 
Breslow thickness greater than 0.75 mm was significantly greater for noncompliance 
melanomas compared with regular-screen melanomas (OR 4.8). Noncompliance has 
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primary melanoma,18 and in the long-term (dermatoscopic) follow-up of patients with 
atypical pigmented lesions19,20 as well. 
 A considerable proportion of melanomas (20%) was diagnosed between scheduled 
screens. The majority of these interval melanomas was detected by patients themselves after a 
median interval of 5 months since the last screen. The Breslow thickness of interval melanomas 
was comparable with that of regular-screen melanomas. This was probably facilitated by 
the fact that participants of the surveillance program were repeatedly educated about the 
 characteristics of melanoma and instructed to perform regular skin self-examinations and 
promptly return to the clinic in case of symptomatic, changing, or new fast-growing lesions. 
 The large number of interval melanomas raises the question whether the standard 
screening interval of our surveillance program (12 months) is adequate. In this study the 
median screening interval of regular-screen melanomas was 5 months, because most 
tumors were diagnosed in patients who were under intensified surveillance because of a 
previous melanoma. Our results suggest that the majority of melanomas became 
detectable within 6 months after the preceding screen. Paradoxically we found that 
tumor thickness was not correlated with the length of the screening interval for intervals 
less than 24 months. This may have been a result of self-selection bias, however, as patients 
with a worrisome lesion are more likely to return to the clinic before the scheduled screen 
(interval melanomas) and are less likely to be noncompliant with follow-up instructions. It 
may also indicate that health education or increased awareness as a result of earlier 
melanomas enabled patients to determine themselves when to return. Alternatively this 
finding could be explained by the growth pattern of melanomas. It has been postulated 
that most melanomas (except for nodular melanomas) initially only exhibit radial 
expansion, without substantial vertical expansion.21 
 Based on this theory it could be argued that melanomas can be detectable for a long 
time, before a substantial increase in their Breslow thickness occurs. 
Our study had a retrospective design and as a consequence classification of melanomas 
into different screening categories was dependent on completeness of data in patient 
charts. To limit the number of misclassifications we were very restrictive in categorizing 
doubtful cases and therefore 15% of surveillance melanomas were not further categorized. 
Our results suggest a number of ways to improve the surveillance program. First, it is 
potentially very rewarding to increase efforts to improve patients’ compliance with 
follow-up instructions. Second, early detection of clinically atypical and fast-growing 
melanomas may be promoted by instructing patients to report to the clinic in case of any 
changing or new (fast-growing) lesion. As a final point, we believe it is debatable whether 
our standard screening interval should be shortened from 12 to 6 months. On the one 
hand the majority of melanomas seemed to be detectable within 6 months after the 
preceding screen, so a shorter interval would advance melanoma detection. In addition, 
compliance with follow-up instructions may improve with shorter screening intervals.19 
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 On the other hand it is unknown whether shortening of the screening interval would 
result in detection of tumors in a more favorable stage.22 Moreover, adequate health 
education and promotion of skin self-examination may be a more cost-effective alternative 
than decreasing the screening interval. Further studies will be required to answer these 
questions. 
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Abstract
Objective:
To investigate the efficacy of a program launched in 1989 by the foundation for the 
Detection of Hereditary Tumours (NFDHT) aimed at the surveillance of members of 
melanoma families and to compare the melanoma detection rate in families with different 
clinical and genetic characteristics. 
Patients and Methods:
From the NFDHT 72 families were selected. A total of 450 individuals were followed for 15 
years between 1992 and 2008 at 85 hospitals throughout the Netherlands.. 
Results:
During follow-up 52 invasive melanomas were diagnosed in 37 individuals. Ten year 
cumulative melanoma incidence was 10.2% (95% CI: 6.9 – 13.5). Family members with a 
history of melanoma had a higher probability of being diagnosed with melanoma than 
their first degree relatives without a history of melanoma (HR: 3.9,  95% CI 2.0 – 7.7).
Median Breslow thickness of surveillance-detected invasive melanomas was 0.50 mm 
compared to 0.94 mm in pre-surveillance index melanomas. None of the patients with 
surveillance-detected melanomas died of melanoma during follow-up (median: 4.2 yrs).
Melanoma detection rate was higher in families with a germline CDKN2A mutation 
compared to CDKN2A wildtype families (HR: 3.6, 95% CI: 1.4 – 9.0) and borderline non-
significantly higher for families with ≥ 3 affected family members compared to 2-case 
families (HR: 2.2, 95% CI: 0.9 – 5.0). 
Conclusion:
Our findings are in support of a beneficial effect of surveillance on tumour thickness at 
diagnosis and survival. Members of CDKN2A mutated families may need more stringent 
surveillance than members of CDKN2A wildtype families.
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Introduction
Being a member of a family with a hereditary predisposition for cutaneous malignant 
melanoma (CMM) is one of the main risk factors for melanoma. Up to 10% of all melanoma 
cases have been reported to occur in families.1 
 The prognosis of melanoma patients is highly dependent on the stage at diagnosis.2 
Early melanomas can be cured by a local excision with adequate margins, but for 
metastatic melanoma the outcome is generally poor. Early detection is considered the 
most effective way to prevent melanoma mortality. In 1989 a national registry for familial 
melanoma was established at the Netherlands Foundation for the Detection of Hereditary 
Tumours (NFDHT) in order to promote the detection and surveillance of members of 
melanoma families throughout the Netherlands. Regular surveillance, consisting of a 
minimum of annual total skin examinations complemented by skin self-examinations, has 
been recommended for all family members with a history of melanoma and their first 
degree relatives (parent, siblings and children).
So far, two high-penetrance melanoma susceptibility genes associated with an autosomal 
dominant inheritance have been identified. Pathogenic germline mutations in the tumour 
suppressor gene CDKN2A (MIM# 600160) are detected in approximately 39% of families 
with ≥3 melanoma cases, and have an estimated penetrance of 67% by the age of 80 
years.3,4 Mutations in the oncogene CDK4 (MIM# 123829) have been detected only in few 
families (estimated 2%). For the majority of families the genetic background has not been 
fully clarified, but appears to be mostly the result of a combination of low (e.g. MC1R) and 
intermediate (e.g. MITF) risk modifier genes, and (possibly) some rare high penetrance 
genes.5,6 In families without a pathogenic germline mutation, melanoma susceptibility is 
suggested by familial clustering of patients with melanoma, but cannot be confirmed by 
genetic testing and therefore remains a clinical diagnosis. 
 Besides genetic differences, clinical experience learns that melanoma pedigrees 
might also be characterized by clinical differences concerning the number of melanoma 
patients and the age of melanoma diagnosis of the affected relatives. It is probable that 
genetic and clinical family characteristics are related to the magnitude of melanoma risk 
of family members. To the best of our knowledge no prospective studies on these issues 
have been published.
The goal of this study was to investigate the efficacy of surveillance and to compare the 
detection rate of melanomas in families with different clinical and genetic characteristics. 
Analyses were based on prospective NFDHT data of 450 individuals from 72 melanoma 
families that were followed for 15 years between 1992 and 2008 at 85 hospitals throughout 
the Netherlands.
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Patients and methods
Data collection
The organization and methods of the NFDHT have been published elsewhere.7,8 In brief, 
physicians from all parts of the Netherlands refer families suspected for familial melanoma 
to the registry. Genealogical studies are performed and all reported malignancies are 
verified by medical records. A genetic predisposition to melanoma is suspected if a family 
consists of a patient with invasive CMM with at least one first degree relative with invasive 
CMM or two additional relatives with invasive CMM. If these criteria are met, the registry 
monitors the continuity of the surveillance program for all family members with a history 
of melanoma and their unaffected first degree relatives by annually sending letters to the 
responsible clinician (mostly dermatologists). In return these clinicians report the results of 
surveillance and histo-pathologic examination.
 From the NFDHT 72 families were selected based on the studied clinical and genetic 
familial characteristics (see below). Families were eligible if they contained a minimum of 
2 first degree relatives with confirmed invasive CMM. All family members with: 1. age 12 
years or older, 2. either having a personal history of melanoma (affected relative), or being 
an unaffected first degree relative of a melanoma patient. 3. registration at the NFDHT, and 
4. having been subjected to at least one skin examination prior to the end date of the 
study (1-1-2008), were included in the study. Family-, patient-, tumour- and follow-up data 
were ascertained from the NFDHT database. For all individuals that were lost to follow-up, 
letters were sent to their clinician, and in case of no reply, to their general practitioner to 
obtain additional follow-up data. 
Analyses
Cumulative melanoma incidence was calculated using the Kaplan Meier method. Survival 
times were calculated from the date of registration at the NFDHT until the date of 
melanoma diagnosis or last date of follow-up (censored). For patients with multiple 
melanomas only the first surveillance detected melanoma was included in the analyses.
Breslow tumour thicknesses of surveillance detected CMM were compared to pre-surveil-
lance index CMM, which consisted of the first melanoma of the first two CMM patients 
from each family. For this purpose multivariate linear regression and binary logistic 
regression analyses were used. In the linear regression analyses a log-transformed Breslow 
thickness was used. Since differences in the log-transformed variable translate to 
multiplication factors on the original scale, results are reported as multiplication factors on 
the original scale. We adjusted for gender, age at diagnosis, order (first or subsequent 
melanoma) and year of diagnosis. Generalized estimating equations (GEE) were used to 
correct for within-patient correlations.9
 We compared the melanoma incidence in families with different genetic and clinical 
characteristics by investigating: 1. Familial CDKN2A mutation status; coded as positive, 
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negative (CDKN2A wildtype) or unknown (in case no genetic testing had been performed). 
All members from a single family were coded equally for this covariate, independent of 
personal test results. 2. The number of affected relatives (melanoma patients); families 
were categorized as 2-case families in case of 2 first degree relatives with melanoma, 
without additional first or second degree relatives with melanoma. In case of one or more 
additional first or second degree relatives with melanoma, families were categorized as 
≥3-case families. 3. The age at melanoma diagnosis of the youngest melanoma patient in 
the family; families were divided in two categories: youngest melanoma diagnosis at age 
younger or older than 30 years.
 Correlation of these three family characteristics with cumulative melanoma incidence 
were analysed using multivariate Cox regression analyses with covariates: gender, age, 
history of melanoma, family CDKN2A mutation status, number of affected relatives, and 
age of youngest melanoma patient < or ≥30 yrs. To adjust for changes in familial charac-
teristics during follow-up, the follow-up of patients was split up into disjoint (hence 
independent) follow-up intervals with the moment of change in familial characteristics as 
stopping time, and analyzed using “delayed entry”. Two time dependent covariates were 
used, one for the number of affected relatives and one for age of the youngest melanoma 
patient. Generalized estimating equations (GEE) were used to correct for within-family 
correlations.9 Based on these analyses adjusted cumulative melanoma incidences were 
calculated for different risk categories.
 All analyses were performed with SPSS 17.0 and R 2.13.0. The package geepack was 
used for the calculation of adjusted standard errors in R.10 Statistical significance was 
determined at α = .05, and all tests were two-sided. For analyses in which more than two 




In total 450 family members (197 males, 253 females) were included in the study. They 
consisted of 124 patients with a history of melanoma and 326 unaffected first degree 
relatives of patients with a history of melanoma. Mean age at registration was 39.7 years 
(range 12.0 – 80.4 yrs, SD: 15.7 yrs). Median follow-up was 6.3 years (range 0.1 – 15.1 yrs). 
Follow-up was complete for 336 patients (75%). Eleven patients died during follow-up 
(details below). For 6 members of CDKN2A mutated families participation in the surveillance 
program was discontinued after they were tested negative for the mutation.
Data on CDKN2A mutation status was available for thirty-four families (47%). In 15 families 
(92 patients) the p16-Leiden mutation (c.225-243del19) in the CDKN2A gene was detected.11 
In 19 families (138 patients) melanoma patients were tested negative for a mutation in 
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CDKN2A. For the remaining 38 families (220 patients) no data on the CDKN2A gene 
mutation status was available. There were no families with pathogenic CDKN2A mutations 
other than the p16-Leiden mutation, unclassified variants or CDK4 mutations included in 
the study. At the time of registration, 49 families (68%) classified as 2-case families, and 23 
families (32%) as ≥3-case families. During follow-up eight 2-case families (16%) became 
≥3-case families as additional family members were diagnosed with melanoma. In 32 
(44%) of the 72 families the youngest melanoma patient was diagnosed with melanoma 
before the age of 30 years.
Mean age at diagnosis of (first) melanomas was 38.1 years (SD: 12.9, range: 16.5 – 69.3 yrs) 
in CDKN2A mutated families, 43.2 years (SD: 14.3 yrs, range: 16.4 – 78.2 yrs) in gene-tested 
CDKN2A wildtype families, and 42.8 years (SD: 13.0, range: 19.7 – 75.6 yrs) in untested 
families (n = 203, including all first melanomas of included family members and index 
melanomas). The differences in mean age at diagnosis according to CDKN2A mutation 
status was not statistically significant (p = 0.11, using a one-way ANOVA test). Of the 203 
first melanomas, 2.5% (n = 5) were diagnosed before age 20 years and 3.4% (n = 7) after 
age 70 years.
Results of surveillance
During follow-up 37 patients (8%) were diagnosed with a total of 52 invasive melanomas 
(table 1). Twenty-nine patients were diagnosed with a single melanoma, four patients with 
two melanomas, one patient with three melanomas, and three patients with four 
melanomas. In addition five in situ melanomas were diagnosed, which were not included in 
the analyses.
 Twenty-three (62%) of the 37 patients that were diagnosed with invasive melanoma 
during follow-up, had a history of melanoma prior to registration at the NFDHT. Ten year 
cumulative melanoma incidence during surveillance was 10.2% (95% CI: 6.9 – 13.5).
The median Breslow thickness of surveillance-detected melanomas (n = 51, 1 missing 
value) was 0.50 mm (range 0.25 – 2.60 mm), compared to 0.94 mm (range 0.18 – 6.00 mm) 
for index melanomas (n = 124). The Breslow thickness of surveillance-detected melanomas 
was significantly thinner than that of index melanomas (multiplication factor 0.65, 95% CI 
0.44 – 0.96, p = 0.033).
 Of the surveillance-detected melanomas 22% (n = 11) had a Breslow-thickness > 1.00 mm, 
compared with 49% (n = 61) of index melanomas. The higher proportion of melanomas 
> 1.00 mm among index cases was not statistically significant (odds ratio 2.50, 95% CI 0.61 
– 10.29, p = 0.204).
Eleven patients (2.4%) died during follow-up. For seven patients cause of death was 
metastasized melanoma. These patients all had their melanoma before registration and 
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60005 Male Unknown 1 49,3 59,6 Unknowne
60008 Female Unknown 1 49,0 53,7 0,40
60020 Male Unknown 1 15,9 21,1 1,00
60021 Female Unknown 2 17,7 26,01 / 27,92 0,621 / 1,052
80007 Male Unknown 1 42,0 43,7 0,49
130033 Male No 1 63,0 76,5 0,27
240003 Male Unknown 1 48,0 55,4 0,40
390014 Female Yes 1 43,3 49,2 0,40
410007 Female No 1 60,0 62,3 1,40
420001 Male No 2 40,4 43,41 / 46,62 0,501 / 0,702
480019 Male Unknown 1 40,9 44,3 0,50
530099 Female No 1 37,0 37,7 0,40
630025 Female Unknown 1 29,0 30,4 0,50
770004 Female Yes 1 27,9 35,9 0,50
880006 Male Unknown 1 47,8 54,7 0,32
900005 Female Yes 4 33,3 38,41 / 38,41 / 
40,02 / 40,43
0,831 / 0,721 / 
1,002 / 0,403
900006 Male Yes 4 33,1 35,31 / 39,22 / 
39,22 / 42,13
0,851 /  2,602 / 
2,002 / 0,503
1030001 Male Yes 1 38,5 43,3 0,45
1050001 Male No 1 61,6 70,6 0,35
1330003 Female Unknown 1 52,6 56,0 0,35
1660002 Female Unknown 1 47,0 56,0 0,45
1890002 Female Unknown 1 49,1 54,0 0,50
1890028 Female Unknown 2 51,4 53,81 / 54,22 0,791 / 0,672
1910006 Male Unknown 1 44,6 49,8 0,40
1920018 Female Unknown 1 35,1 37,3 1,10
2110001 Male Yes 4 43,1 43,11, d / 43,72 / 
46,53 / 47,14
0,501 / 0,702 / 
0,603 / 0,754
2190002 Female Yes 1 52,8 55,0 0,42
2190016 Male Yes 2 57,6 60,11 / 62,82 0,501 / 1,202
2580005 Female Unknown 1 28,5 30,8 0,60
2630102 Male Yes 1 43,7 46,9 0,30
2650019 Female Unknown 1 33,0 33,4 0,25
2770101 Female Yes 1 52,7 56,7 0,25
2840003 Male Yes 1 33,9 35,2 0,26
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none of them was diagnosed with a subsequent primary melanoma during follow-up. 
Two patients died from oesophagus carcinoma. For two patients cause of death was 
unknown, but neither of them was diagnosed with melanoma during follow-up. None of 
the 37 patients that were diagnosed with melanoma during follow-up died of melanoma 
(median follow-up after diagnosis: 4.2 yrs, range 0.0 – 11.4 yrs, follow-up complete for 33 
patients, 4 patients lost to follow-up).
Risk factors
In table 2 the results of the multivariate Cox proportional hazard analyses for family 
members with a history of melanoma and first degree relatives are presented separately. 
The analyses showed a significantly increased melanoma detection rate for family 
members with a history of melanoma who were member of a family in which a relative 
had been diagnosed with melanoma before age 30 (hazard ratio (HR) 3.6, table 2). An 
increased melanoma detection rate was also seen for family members with a history of 
melanoma from CDKN2A-mutated families compared to families without a CDKN2A 
mutation (HR 5.9), though this finding was not statistically significant after correction for 
multiple testing. For first degree relatives, no significant personal or familial risk factors 
could be identified.
 An additional Cox proportional hazard analysis combining the data of affected 
relatives and first degree relatives (table 3) identified a personal history of melanoma (HR 
3.93) as the main predictor of melanoma detection. Ten year cumulative melanoma 
incidence was 23.3% (95% CI: 13.9 – 32.7) for family members with a history of melanoma 
and 6.0% (95% CI: 2.7 – 9.3) for first degree relatives. In addition, melanoma detection rate 
was significantly higher in family members from families with the p16-Leiden mutation 
compared with family members from families without a CDKN2A mutation (HR 3.6). 
Adjusted ten year cumulative melanoma incidence was 16.2% for CDKN2A mutated 
families, 7.6% for untested families, and 4.8% for CDKN2A wildtype families (figure 1).













2840103 Female Yes 3 26,2 27,91 / 28,72 / 
29,33
0,321 / 1,402 / 
0,923
3030101 Male No 1 47,6 48,6 1,94
3080065 Male Yes 1 62,9 63,2 1,60
3160009 Female Yes 1 19,4 20,2 0,55
a ; Familial CDKN2A mutation status, b ; Number of melanomas during follow-up, c ; Breslow thickness in millimetres, 
d ; The first melanoma of patient 2110001 was diagnosed one month after registration, e ; Because of low clinical 
suspicion this lesions was removed by curettage, and the pathologist was unable to determine the Breslow 
thickness, 1 ; 1st melanoma, 2 ; 2nd melanoma, 3 ; 3rd melanoma, 4 ; 4th melanoma 
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 A sub-analysis was performed in which members from CDKN2A mutated families 
were excluded (table 4). In this analysis a personal history of melanoma again came up as 
the main predictor of melanoma detection. There were borderline non-significant 
differences in melanoma detection rate between patients from ≥3-case families and 
2-case families (p = 0.074), with an adjusted ten year cumulative melanoma incidence of 
9.7% in ≥3-case families and 4.6% in 2-case families.
Table 2   Multivariate analyses of personal and familial risk factors for melanoma of 
affected relatives and first degree relatives.
Affected relatives# First degree relatives
Covariate HR (95% CI)* P HR (95% CI)* P
Family size ≥ 3 cases 0.7 (0.3 – 1.7) 0.44 1.5 (0.5 – 4.4) 0.47
Age youngest relative < 30 yrs 3.6 (1.4 – 9.4) 0.01$ 0.6 (0.2 – 1.5) 0.29
No CDKN2A mutation in family 1.0
    CDKN2A mutation in family 5.9 (1.2 – 30.2) 0.039% 2.4 (0.7 – 8.3) 0.17
    Familial CDKN2A status
    unknown
2.7 (0.5 – 13.9) 0.23 1.0 (0.3 – 4.0) 0.99
Male gender 2.0 (0.8 – 5.0) 0.10 0.4 (0.2 – 1.2) 0.12
Age (years) 1.0 (1.0 – 1.1) 0.97 1.0 (1.0 – 1.1) 0.58
# Affected relatives = relatives with a history of melanoma; * HR (95% CI); Hazard Ratio (95% Confidence Interval), 
$ statistically significant, % not statistically significant after adjustment for multiple testing (significance level at 0.017
Table 3   Multivariate analyses of personal and familial risk factors for melanoma: 
affected and first degree relatives combined.
Covariate HR (95% CI)* P
Personal history of melanoma 3.9 (2.0 – 7.7) < 0.001$
Family size ≥ 3 cases 1.0 (0.5 – 2.1) 0.99
Age youngest relative < 30 yrs 1.8 (0.9 – 3.5) 0.090
No CDKN2A mutation in family 1.0
    CDKN2A mutation in family 3.6 (1.4 – 9.0) 0.006$
    Familial CDKN2A status unknown 1.6 (0.6 – 4.3) 0.33
Male gender 1.2 (0.7 – 2.2) 0.56
Age (years) 1.0 (1.0 – 1.0) 0.81
* HR (95% CI); Hazard Ratio (95% Confidence Interval), $ statistically significant
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Discussion
In this study we report the results of surveillance of 72 families selected from the NFDHT 
Dutch national registry for familial melanoma. Overall 450 individuals were followed for 15 
years between 1992 and 2008 at 85 hospitals throughout the Netherlands. Only few 
prospective studies have investigated the effectiveness and safety of surveillance of 
melanoma families and to the best of our knowledge this is the first prospective study to 
compare melanoma detection rates in families with different clinical and genetic charac-
teristics.
The 10 year cumulative melanoma incidence during surveillance was 10.2%, which affirms 
the high melanoma risk and necessity of adequate surveillance of these families. Family 
members with a history of melanoma at the moment of entering surveillance were more 
likely to be diagnosed with melanoma during surveillance than their unaffected first 
degree relatives (HR: 3.9,  95% CI 2.0 – 7.7).
Patient survival is strongly correlated with Breslow tumour thickness, which is illustrated 
by the fact that 10-year survival is 92% in case of melanomas ≤ 1.00 mm, and 50% if > 4.00 
mm.2 In our study, surveillance-detected invasive CMM’s had a statistically significant, 
almost 40%, thinner Breslow thickness (median 0.50 mm) than melanomas of pre- 
surveillance index patients (median 0.94 mm). Moreover, the proportion of melanomas 
with a Breslow thickness > 1.00 mm was 22% in surveillance-detected cases, compared to 
49% in index cases, though the difference was not statistically significant after correction 
Table 4   Multivariate analyses of personal and familial risk factors for melanoma in 
families without a CDKN2A mutation and untested families (families with a 
CDKN2A mutation excluded).
Covariate HR (95% CI)* P
Personal history of melanoma 4.2 (1.8 – 9.7) < 0.001$
Family size ≥ 3 cases 2.2 (0.9 – 5.0) 0.074
Age youngest relative < 30 yrs 0.8 (0.4 – 1.5) 0.42
No CDKN2A mutation in family 1.0
    CDKN2A mutation in family excluded
    Familial CDKN2A status unknown 1.9 (0.8 – 4.7) 0.15
Male gender 1.3 (0.6 – 3.0) 0.49
Age (years) 1.0 (1.0 – 1.0) 0.82
* HR (95% CI); Hazard Ratio (95% Confidence Interval), $ statistically significant
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for possible confounders. The median thickness of surveillance-detected melanomas in 
our study was comparable to other studies (0.50 mm – 0.56 mm)  with equally or more 
stringent surveillance regiments.12,13,14,15,7 None of the patients with surveillance-detected 
melanomas died of melanoma during follow-up. This finding needs to be viewed with 
some reserve as the duration of follow-up was limited (median 4.2 years), 12% of melanoma 
patients were lost to follow-up and lead time bias may have affected our results. The 
overall picture of our findings suggests that surveillance results in the detection of a 
considerable number of CMM, mostly diagnosed at an early stage and with a generally 
good prognosis.
Figure 1   Cumulative melanoma incidence during surveillance according to familial 
CDKN2A mutation status
No mutation; CDKN2A wildtype, Mutation: p16-Leiden mutation (c.225-243del19) in CDKN2A, Unknown; family 
has not been genetically tested.
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Less than 40% of melanoma families are characterized by mutations in the high penetrance 
melanoma susceptibility genes CDKN2A and CDK4, and clinical characteristics like the 
number of affected relatives and age of melanoma diagnoses, differ considerably between 
pedigrees. As the clinical significance of these genetic and clinical differences have not 
been fully clarified, it is uncertain if and how they should affect surveillance guidelines. We 
compared melanoma detection rates during surveillance in clinically and genetically 
different families in order to support the development of a tailored surveillance program. 
The melanoma detection rate was significantly higher in families with a germline mutation 
in CDKN2A compared to CDKN2A wildtype families. Adjusted ten year cumulative 
melanoma incidence was 16.2% in CDKN2A mutated families compared to 4.8% in 
CDKN2A wildtype families. This finding is in accordance with a relatively higher melanoma 
risk in families with a high-penetrance melanoma susceptibility gene mutation compared 
to families lacking such mutation and in which melanoma risk is most likely the result of 
low and intermediate risk modifier genes. The relatively high melanoma detection rate in 
CDKN2A mutated families may also, to some extent, be attributable to the selection of 
high risk individuals for surveillance as a result of genetic testing. In our dataset 6 patients 
(6.5%) from CDKN2A mutated families were released from surveillance during follow-up 
when they were tested negative for the mutation. 
 In a subanalysis of CDKN2A wildtype and untested families a borderline non-signifi-
cant two-fold increased melanoma detection rate (HR: 2.2, 95% CI: 0.9 – 5.0) in ≥3-case 
compared to 2-case families was found. It seems plausible that the familial melanoma risk 
is reflected in the number of affected relatives. Statistical non-significance of this finding 
may be due to lack of power, but more studies are needed to confirm these results. 
Our study had several limitations. Only 47% (34/72) of families were genetically tested. Our 
data suggest that families with more affected relatives were more likely to be tested (the 
proportion of ≥3-case families in p16-Leiden mutation families, CDKN2A wildtype families 
and untested families were 40% (6/15), 42% (8/19) and 24% (9/38) respectively). This 
selection bias most likely resulted in an underestimation of the difference in melanoma 
detection rate between CDKN2A mutated and wildtype families. We performed 
sub-analyses (data not shown) in which only gene-tested families were included, but this 
had little effect on the results.
 Prevention of melanomas due to excision of changing and suspicious nevi as happens 
regularly in daily practice, could not be accounted for in this study design, and may have 
resulted in an underestimation of the efficacy of surveillance. To limit the effect of 
overdiagnosis, melanomas in situ were excluded from the analyses.
Concluding, our findings are in support of a beneficial effect of surveillance on tumour 
Breslow thickness at diagnosis and survival of members of melanoma families. Our results 
suggest that surveillance should start during puberty and may need to be continued 
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beyond seventy. Surveillance may need to be more frequent in melanoma patients 
compared to their first degree relatives without a history of melanoma and CDKN2A 
mutated families may need more stringent surveillance than CDKN2A wild-type families. 
Compared to other melanoma families, CDKN2A wild-type two-case families appear to be 
at a relatively low risk. More studies are needed to facilitate the development of a tailored, 
cost-effective surveillance program for familial melanoma.
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Abstract
Background:
Life time melanoma risk of mutation carriers from families with a germline mutation in the 
CDKN2A gene is estimated to be 67%. The necessity to include family members in a 
melanoma surveillance program is widely endorsed, but there is no consensus on which 
family members should be invited. 
Methods:
In a retrospective follow-up study we investigated the yield of surveillance of first- and 
second-degree relatives of melanoma and pancreatic cancer patients from 21 families 
with the ‘p16-Leiden’ CDKN2A mutation. Melanoma incidence rates were compared with 
the general population. 
Results:
Three-hundred and fifty four first-degree relatives and 391 second-degree relatives were 
included. Forty-five first-degree relatives and 11 second-degreesecond-degree relatives 
were diagnosed with melanoma. Most (72%) of second-degree relatives diagnosed with 
melanoma, had become a first-degree relative before diagnosis, due to the occurrence of 
a melanoma in a parent or sibling. Overall, melanoma incidence rate was 2.1 per 1000 
person years [95% confidence interval (CI), 1.2-3.8] in family members still being second-
degreerelatives at diagnosis, compared with 9.9 per 1000 person years (95% CI, 7.4-13.3) in 
first-degree relatives. The standardized morbidity ratio for melanoma of second-degree 
relatives compared with the general population was 12.9 (95% CI, 7.2-23.4). 
Conclusion:
Second-degree relatives from families with the p16-Leiden mutation in CDKN2A have a 
considerably increased melanoma risk compared to the general population.
Impact:
This study provides justification for the surveillance of second-degree relatives from 
families with a CDKN2A germline mutation. 
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Introduction
Familial melanoma is one of the strongest risk factors for cutaneous melanoma. 
Approximately 10% of melanoma cases are found in families with two or more patients 
with melanoma.1 In up to 40% of families with three or more melanoma cases a mutation 
in the high penetrance melanoma susceptibility gene CDKN2A (MIM# 600160) is found.2 
With respect to melanomagenesis, CDKN2A has an incomplete penetrance that has been 
estimated to be 0.67 by age 80 years.3 In the Netherlands, by far the most prevalent 
CDKN2A germline mutation is a specific founder mutation (c.225-243del19),4 known as the 
p16-Leiden mutation. The p16-Leiden mutation is associated with a very high melanoma 
risk, comparable with other CDKN2A mutations, and with a cumulative risk of pancreatic 
cancer of 17% by age 75.5 
Because of the increased melanoma risk and expected benefit of surveillance,6,7 regular 
surveillance of members of familial melanoma families is widely advocated.8,9 In the 
Netherlands, the first surveillance program for familial melanoma was initiated at the 
Leiden University Medical Center (LUMC, Leiden, the Netherlands) in 1981. Individuals that 
were invited to the program encompassed patients with melanoma, their first-degree 
relatives (parents, siblings and children) as well as their second-degree relatives 
(grandparents, uncles, aunts, nieces, nephews and grandchildren). Assuming an autosomal 
dominant pattern of inheritance (as was later proven to be the case for CDKN2A germline 
mutations), first and second-degree relatives have a 50% and 25% chance of carrying the 
genetic risk factor.
 The 1981 surveillance guidelines were based on the estimation that life time melanoma 
risk of mutation carriers approximated 100%, implying an almost 25% life time melanoma 
risk for second-degree relatives. Since 1981, the recommendation for surveillance of 
second-degree relatives has remained unchanged.10 
 Since the year 2000 (predictive, CDKN2A) DNA testing of asymptomatic family members is 
available in the Netherlands. Predictive DNA testing facilitates the selective offering of 
surveillance to those family members at highest risk of melanoma and therefore has the 
potential to greatly increase surveillance (cost-) effectiveness. An earlier study at our 
institution suggested however that the majority of relatives either do not opt for genetic 
testing, or at an age (i.e., average age 48 years) that lies considerably beyond the young age 
of onset (i.e. median age of melanoma diagnosis 39 years) in CDKN2A mutated families.11,12 
As a consequence second-degree relatives have continued to present for surveillance.
To the best of our knowledge, surveillance of second-degree relatives has not been 
addressed in (familial) melanoma guidelines from other countries and is unusual for other 
types of hereditary cancer syndromes as well. Given this discrepancy between Dutch and 
foreign guidelines, and to evaluate current surveillance recommendations, we performed 
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a retrospective follow-up study to evaluate the yield of surveillance of second-degree 
relatives in families with a founder mutation in CDKN2A (the p16-Leiden mutation).
Materials and Methods
Family ascertainment and data collection
Families were ascertained through the pigmented lesion clinic of the department of 
dermatology of the Leiden University Medical Centre (LUMC) from 1980 onward. At the 
clinic family trees were constructed and family members were invited to participate in 
annual total skin examinations. Since 1985, a decade before the identification of the 
p16-Leiden mutation, blood samples have been collected for research purposes. Patients 
consented to this, knowing that carrier information would not be transmitted back to 
them. Clinicians were also kept unaware of gene carrier status.
Pedigree information was updated on a regular basis. Follow-up data were collected, both 
during clinic visits, and in several research projects. Confirmation of melanoma diagnoses 
was gathered through pathology reports and medical records. In 2007 at the event of an 
earlier study, melanomas of mutation negative family members and all tumors with 
missing data, in situ melanomas and lentigo malignas were revised by one of us, a member 
of the pathology panel of the Dutch Melanoma Working Party.7 Further details on family 
ascertainment and the collection of follow-up data have been described elsewhere.5
Inclusion
Inclusion of family members was based on the presence of the p16-Leiden mutation in 
their family and independent of personal CDKN2A mutation status (mutated, wildtype or 
unknown). In the study model all relatives with melanoma or pancreatic cancer were 
regarded (probable) mutation-carriers and mutation status of all other relatives was 
regarded to be unknown. 
First and second-degree relatives of family members with a medical history of invasive 
melanoma, melanoma in situ or pancreatic cancer, were included. A minimum age of 12 
years was required. To minimize selection bias, not only family members undergoing 
regular skin check-ups and participants in research projects at the LUMC dermatology 
department, but also relatives that had not visited the LUMC clinic thus far, were included 
in the study. Data on nonvisiting family members were obtained from their parents, 
siblings or children that did visit the clinic and was collected through questionnaires at the 
occasion of an earlier study.5 No data were available on the extent of participation of 
family members at skin examinations by general practitioners or clinicians at other 
hospitals than the LUMC.
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Analysis of melanoma incidence
Melanoma incidence was analyzed in two ways. In the first analysis we used a model in 
which calculation of follow-up was independent of actual participation in the surveillance 
program. Follow-up times for all relatives started as soon as their family fulfilled the criteria 
for familial melanoma, which was defined as: a minimum of two first-degree relatives with 
either invasive melanoma, or one with invasive melanoma and one with pancreatic cancer, 
or three (non-first-degree) relatives with invasive melanoma or two with invasive melanoma 
and one with pancreatic cancer. End of follow-up was defined as: (i) occurrence of an event, 
i.e. the diagnosis of an invasive or in situ melanoma; (ii) end of follow-up due to closure of the 
study (Jan 1 2004, based on completeness of data collected for an earlier study), lost to 
follow-up, death, a diagnosis of pancreatic cancer (indicating a probable p16-Leiden 
mutation carrier) or having a child or grandchild diagnosed with melanoma or pancreatic 
cancer (indicating a high likelihood of being a p16-Leiden mutation carrier). An additional 
reason for end of follow-up for second-degree relatives consisted of the reclassification as 
first-degree relative. Subsequent follow-up of these relatives was included in the calculation 
of the melanoma incidence rate of first-degree relatives. For relatives with multiple primary 
melanomas, only the first melanoma was included in the analysis.
A second analysis was conducted to calculate the melanoma incidence in first and 
second-degree relatives during actual participation in the surveillance program at the 
LUMC dermatology department. It was anticipated that this sub-population was enriched 
for individuals with an increased likelihood of being diagnosed with melanoma, as it was 
expected that family members with a suspicious nevus or large numbers of (atypical) nevi 
were more likely to attend surveillance. For this sub-analysis we used data on clinic visits 
spanning from 1993 till 2004, as from 1993 onwards clinic appointments were recorded in 
the LUMC hospital information system.
Statistical analysis
Person years were calculated separately for each category (first- and second-degree relatives) 
and used to compute overall incidence rates and incidence rates per 10 years age groups. 
For second-degree relatives that became first-degree relatives during follow-up, subsequent 
follow-up was added to the person years for first-degree relatives, as described earlier. 
The overall HR for first-degree relatives to develop a melanoma compared with second- 
degree relatives corrected for age was estimated using a Cox proportional hazard analysis. 
 Standardized morbidity ratios (SMR) were calculated to estimate the increase in melanoma 
risk in first and second-degree relatives compared to the general population. The SMR 
was computed as the ratio of the observed number of cases in either the first- or 
second-degree relatives over the number of cases expected based on the case rate in the 
general population, after standardization for age and incidence year distribution. General 
population data were based on the reported melanoma incidences (with (near) completeness 
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of data both for invasive and in situ melanomas) per gender and 5-years age categories 
between 1989 and 2003 at the Netherlands Cancer Registry.13 
To analyze the probability of second-degree relatives to become a first-degree relative 
before melanoma diagnosis a multi-state analysis was conducteded with age as time 
scale.14 Four states are considered: (i) second-degree relative without melanoma, (ii) 
first-degree relative without melanoma, (iii) second-degree relative with melanoma, and 
(iv) first-degree relative with melanoma. Transitions are possible from state 1 to 2 and 3, 
and from state 3 to 4. Non-parametric estimates of the transition hazards were obtained 
using the package mstate, version 0.2.6 for R.15 Subsequently, state occupation probabilities 
(of the four states) over time were calculated, given second-degree relative without 
melanoma at t=0, based on the Aalen-Johansen estimator. 
Analyses were performed with STATA (version 11), SPSS (version 17) and R (version 2.15.0).
Results
Data characteristics
A total of 21 families was included in the study. Twelve families were included with two 
first-degree relatives with melanoma, 2 families with three (non-first-degree) relatives with 
melanoma, 5 families with two first-degree relatives, one with melanoma and one with 
pancreatic cancer, and 2 families with two relatives with melanoma and one or more 
relatives with pancreatic cancer.  
 On the basis of the pedigrees of these 21 families there were 789 eligible family 
members. Of these, 667 could be included: 354 first-degree relatives (including 78 relatives 
that turned from second into first-degree relative during follow-up) and 391 second-degree 
relatives. Data characteristics are reported in table 1.
A total of 56 relatives (45 first-degree, 11 second-degree relatives) were diagnosed with 
melanoma during follow up; 50 invasive and 6 in situ melanomas (5 in first-degree, 1 in 
second-degree relatives). Three additional lesions initially diagnosed as in situ melanoma 
were excluded, as they were reclassified as benign melanocytic lesions after histologic 
revision. Median age of melanoma diagnosis was 39 years (range 15 – 72) in first-degree 
relatives and 26 years (range 16 – 44) in second-degree relatives.
 In case of the first-degree relatives, 13 patients were diagnosed with melanoma (29%) 
at their first clinic visit, 22 patients (49%) during surveillance, and for 10 patients (22%) the 
moment of melanoma detection could not be verified. For second-degree relatives the 
moment of melanoma detection was; 1 (9%) first clinic visit, 9 (82%) during surveillance 
and 1 (9%) unverifiable.
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Melanoma incidence
Overall, melanoma incidence rate was 9.9 per 1000 person years (95% CI, 7.4 to 13.3) in 
first-degree relatives and 2.1 per 1000 person years (95% CI, 1.2 to 3.8) in second-degree 
relatives (Table 2). Overall HR of first-degree relatives to develop a melanoma compared 
with second-degree relatives, adjusted for age, was found to be 5.1 (95% CI = 2.6 to 10.0, 
P < 0.001). 
 Overall SMR for melanoma compared with the general population was 101.0 (95% CI, 
55.9 – 182.3) in first-degree relatives (observed: 45, expected: 0.76), and 12.9 (95% CI, 7.2 – 23.4) 
in second-degree relatives (observed: 11, expected: 0.53).
Melanoma detection rates during surveillance
We conducted a subanalysis of relatives that had been under surveillance at the LUMC 
dermatology clinic. A total of 128 of 277 first-degree relatives (46%) and 113 of 286 second- 
degree relatives (40%) with follow-up data between 1993 and 2004, attended the 
surveillance program at least once within this period.
The number of clinic visits per year was 1.12 for first-degree relatives (705 clinic visits in 627 
person years) and 0.91 for second-degree relatives (536 clinic visits in 588 person years). 
Median age of first and second-degree relatives was 32.6 years and 28.8 years, respectively. 






Total number of relatives in 
the pedigrees
364 (286 + 78*) 503 867 (789 *)
Number of relatives 
included in the study
354 (97%) 391 (78%) 745 (667*)
Total follow-up (person 
years)
4531 5280 9811
Number of relatives with 
complete follow-up
319 331 650
Length of follow-up 
median (range)
12.8 y (0.0 – 36.4) 14.9 y (0.0 – 25.7) -
Age at inclusion median 
(range)
33 y (12 – 78) 19 y (12 – 71) -
Gender 177 males (49.7% ) 203 males (52.2%) -
Legend: * Seventy-eight individuals changed from second- to first-degree relative during follow-up. Their 
person years as second-degree relative were added to the totals of second-degree relatives and person years as 
first-degree relative to the totals of the first-degree relatives.
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Melanoma incidence rate was calculated to be 22.3 / 1000 person years (95% CI, 13.2 – 
37.7) in first-degree relatives and 8.5 / 1000 person years (95% CI, 3.5 – 20.4) in second-degree 
relatives. Overall HR of first-degree relatives to develop a melanoma compared with 
second-degree relatives, adjusted for age, was found to be 2.6 (95% CI, 0.9 to 7.6, p = 0.070). 
 In family members that had not been under surveillance at the LUMC between 1993 
and 2004, in this period one melanoma was diagnosed in first-degree relatives (n = 149) 
and one melanoma in second-degree relatives (n = 173).
Table 2   Incidence rates of melanoma in first- and second-degree relatives according  
to age
A. Incidence rates of melanoma in first-degree relatives:
Age band No. of melanoma 
case patients
No. of  
person years
Incidence rate  / 1000  
person years (95% CI)
10-19 4 407.1 9.8    (3.7-26.2)
20-29 7 801.5 8.7    (4.2-18.3)
30-39 14 967.1 14.5  (8.6-24.4)
40-49 8 777.3 10.3  (5.1-20.6)
50-59 6 682.5 8.8    (3.9-19.6)
60-69 5 574.0 8.7    (3.6-20.9)
70-79 1 253.8 3.9    (0.6-28.0)
80-89 0 53.1 0       (0-69.0)
90-99 0 14.6 0       (0-252.7)
TOTAL 45 4531.0 9.9    (7.4-13.3)
B. Incidence rates of melanoma in second-degree relatives:
Age band No. of melanoma 
case patients
No. of  
person years
Incidence rate / 1000  
person years (95% CI)
10-19 1 878.5 1.1    (0.2-8.1)
20-29 6 1588.9 3.8    (1.7-8.4)
30-39 2 1551.4 1.3    (0.3-5.2)
40-49 2 838.6 2.4    (0.6-9.5)
50-59 0 267.4 0       (0-13.8)
60-69 0 112.3 0       (0-32.8)
70-79 0 38.2 0       (0-96.6)
80-89 0 5.0 0       (0-737.8)
TOTAL 11 5280.2 2.1    (1.2-3.8)
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Second to first-degree relative transition
During follow up 20% (78/391) of the second-degree relatives became first-degree 
relatives as the result of a new diagnosis of melanoma or pancreatic cancer in one of their 
family members. Median age of transition from second to first-degree relative was 30 
years (range 12-67).
Besides the 11 second-degree relatives that were diagnosed with melanoma while (still) 
being a second-degree relative (median age of diagnosis: 26 years (range 16 – 44), there 
were 11 relatives, who started out as second-degree relative at inclusion, and were 
diagnosed with melanoma after they had become a first-degree relatives (median age of 
diagnosis: 35 years (range 16 – 46). There were no differences between these two groups 
Figure 1   
Figure 1 represents the probability of second-degree relatives to belong to either of four states according to their 
age (12 – 80 years): 1 second-degree relatives who have become first-degree relatives (but were not diagnosed 
with melanoma); 2 second-degree relatives who have become first-degree relatives and were subsequently 
diagnosed with melanoma; 3 second-degree relatives diagnosed with melanoma (as second-degree relative); 
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concerning age at inclusion; (median 15.1 yrs (range 12.0 – 28.4) versus 17.4 yrs (range 12.0 
– 39.3), number of first-degree relatives (parent and siblings); 4 relatives (range 3 – 6) versus 
3 relatives (range 1 – 8), or number of first-degree relatives older than themselves; 2 relatives 
(range 1 – 4) versus 3 relatives (range 1 – 4).
In Fig. 1 the probabilities of second-degree relatives to become a first-degree relative and 
to develop a melanoma as a first or second-degree relative, according to age, are 
presented. Overall 20.8% of individuals that entered follow-up as second-degree relatives 
were estimated to be diagnosed with melanoma at age 80 years, 72.2% of whom had 
been transformed to first-degree relative, before melanoma diagnosis.
Discussion
The goal of this study was to evaluate the yield of surveillance of second-degree relatives 
in melanoma families with the p16-Leiden mutation in CDKN2A. In the Netherlands, 
historically all first and second-degree relatives of patients with melanoma with familial 
melanoma have been recommended to undergo regular skin examinations. Given the 
expected high life time risk and relatively simple, noninvasive screening procedure at 
hand, inclusion of second-degree relatives in the surveillance program seemed logical at 
the time. An intensive literature study suggested that inclusion of second-degree relatives 
is unusual in other countries and for other types of hereditary cancer, 16,17 but we did not 
encounter evidence against inclusion of second-degree relatives either. 
 We report a melanoma incidence rate of 2.1 / 1000 person years for second-degree 
relatives. The relative risk of first-degree relatives (incidence rate: 9.9 / 1000 person years) 
compared with second-degree relatives was 5.1, which was considerably higher than 
anticipated on the basis of Mendelian inheritance (expected RR ≈ 2). To a certain extent 
this can be explained by our finding that 72% of individuals that entered the study as 
second-degree relatives that were later diagnosed with melanoma, became a first-degree 
relative before their melanoma diagnosis. This implies that the majority of melanomas 
diagnosed in (initially) second-degree relatives were diagnosed after their parent or 
sibling became melanoma patient, and would not have been missed if only first-degree 
relatives would have been under surveillance. If transition of second-degree relatives to 
first-degree relatives was neglected, the overall proportion of second-degree relatives 
diagnosed with melanoma at age 80 years was estimated to be 20.8%, which is similar to 
the 17% (a priori) risk that would be expected on Mendelian inheritance (25% of the 
penetrance for melanoma of proven mutation carriers (67%)).3 
 The melanoma detection rate of second-degree relatives that had been under 
surveillance at the LUMC dermatology clinic was considerably higher (8.5 / 1000 person 
years) than the estimate for the second-degree relatives population as a whole (2.1 / 1000 
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person years). It is likely that family members with larger number of (atypical) nevi, who 
have a higher probability of being a mutation carrier and a higher melanoma risk,18,19 are 
more likely to participate in surveillance. However, we have no data on nevus phenotype 
to support this supposition. In addition we expect that relatives with a suspicious lesion 
(i.e. possible melanoma) are more likely to participate in surveillance. This notion is 
supported by the fact that 25% of the melanomas in our study were detected in family 
members who presented at the clinic for the first time. Early diagnosis may have accounted 
for part of the higher melanoma detection rates in second-degree relatives that were 
under surveillance. This is supported by an earlier reported that surveillance of these 
families was associated with lower tumor Breslow thickness.(7) 
 The melanoma risk of second-degree relatives was calculated to be 12.9 -fold that of 
the general population, which is considerably higher than the estimates for individuals 
with established risk factors such as > 5 atypical naevi (relative risk (RR): 6.4) or with > 100 
melanocytic nevi (RR: 6.9).20 
On the basis of the incidence rates from our study, the number of patients needed to be 
screened annually to detect one melanoma (number needed to screen; NNS), was 101 in 
first, and 476 in second-degree relatives. For second-degree relatives that participated in 
the LUMC surveillance program at the time of diagnosis, the NNS was 118. A recent popu-
lation-based skin cancer screening intervention study in the German state of Schleswig-
Holstein involving 360288 screenees, reported a NNS for malignant melanoma of 620.21 
Taking into consideration that this study involved considerably older subjects (mean age 
50 years) that were screened only once, the yield of surveillance of second-degree relatives 
in our study was considerably higher.
 The ultimate goal of melanoma surveillance and screening is to reduce morbidity 
and mortality. With the lack of evidence from randomized controlled studies, there is still 
considerable debate on this subject.22,23 As there are considerable data that suggests 
screening for melanoma does save lives, offering surveillance to selected high risk 
populations seems justified.8
Retrospective follow-up studies like ours are at risk of several biases. We dealt with possible 
family selection bias by excluding probands from the analyses. Consistency of 
(retrospective and prospective) data could be confirmed in an additional analysis (Cox 
proportional hazard analysis with delayed entry, data not shown) as from the time families 
were included in the analysis, melanoma incidence rates were constant over time (a 
straight line fitting within the 95% confidence intervals) for both first and second-degree 
relatives. This was also the case for the probability of second-degree relatives to become 
first-degree relatives. In an attempt to correct for selection bias of persons at increased risk 
of melanoma (as described earlier) relatives that had not been screened at the LUMC were 
included in the analysis.
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 Our study may have been prone to overdiagnosis and misclassification bias.24,25 
However, as all in situ melanomas and melanomas of proven mutation negative family 
members have been revised at the event of an earlier study, we may have reduced mis-
classification to a minimum. At the same time surveillance is likely to prevent melanomas 
as a result of the practice to excise changing and clinically suspicious nevi. Taking these 
consideration into account our results should be viewed with some reserve. It is our overall 
impression however that our data are sound given the fact that the overall cumulative 
melanoma incidence of second-degree relatives at age 80 years approximated the 
expected life-time risk based on data from the literature (see above).
In conclusion, this study provides insights in the family dynamics of surveillance and 
estimates of melanoma incidence rates and relative risks of second-degree relatives from 
CDKN2A mutated families that facilitate the discussion on the selection of relatives for 
surveillance. We belief our results provide justification for the surveillance of second-degree 
relatives from these very high-risk melanoma families. Further research is necessary to sort 
out whether these findings equally apply to families without (or other germline-) 
mutations in the high-penetrance melanoma susceptibility gene CDKN2A.
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MADAM, We read with great interest the recent article about the controversy over the 
explanation of the melanoma epidemic.1 The past decades have witnessed a substantial 
increase in the reported incidence of cutaneous malignant melanoma (CMM) without a 
proportional rise in melanoma mortality in most European countries. The paper suggests 
that the large increase is likely to be due to diagnostic drift which classifies benign lesions as 
stage 1 melanoma.1,2 
Histology is the gold standard for the diagnosis of CMM, but the assessment of small and thin 
melanocytic lesions, that constitute a growing proportion of lesions submitted for histology, is 
problematic, and interobserver agreement is moderate at best.3,4 Histological indicators of 
malignancy have largely been derived from larger lesions, and it is unknown if they are equally 
applicable for small lesions. As the consequences of overdiagnosis are generally limited to a 
small local re-excision and increased patient stress, whereas underdiagnosis results in an 
increased chance of recurrence and death, judgement tends to be skewed towards malignancy.2,4 
In our clinic, members of melanoma families have been under surveillance since 1981. In many 
of these families, a mutation (p16-Leiden) in the high-penetrance melanoma susceptibility gene 
CDKN2A has been identified.5 During surveillance of 37 families with a p16-Leiden mutation, 
melanomas have been diagnosed in 105 genetically tested relatives, 12 of whom (11%) were 
noncarriers. These 12 noncarriers had a total of 13 melanomas. As part of a study on the effect 
of surveillance (manuscript in preparation) the slides of 126 melanomas were reviewed. These 
consisted of all in situ melanomas (n = 63), and invasive melanomas with missing data or of a 
nonsuperficial spreading histological type (n = 52) that had been diagnosed in mutation carriers 
within these 37 families. All melanomas of the 12 noncarriers that were available for histological 
review (seven in situ and four invasive melanomas from 10 patients) were added to the set. 
Slides were revised by a pathologist who is a member of the Dutch melanoma panel (W.J.M.). 
Revisions were performed blinded for the patients’ mutation status. After disclosure of the 
mutation status a disproportionately high proportion of (in situ) melanomas reclassified as 
benign melanocytic lesions turned out to be cases of noncarriers. Eight (seven in situ and one 
invasive) of the 11 melanomas of noncarriers were reclassified as benign (73%), compared with 
only 13 of the other 115 cases (11%). In seven of 10 mutation-negative relatives a history of 
melanoma was therefore not confirmed. 
These results touch on two important issues. Firstly, the value of genetic testing for CDKN2A 
mutations has been discredited because of a reported increased melanoma incidence 
among mutation-negative relatives.6 Our data show that overdiagnosis may account for a 
significant proportion of this observation. Secondly, increased screening and surveillance of 
individuals with a low a priori melanoma risk may result in removal of increased numbers of 
small and histologically equivocal lesions, some of which will be overdiagnosed as cancers 
and (especially in the case of individuals with a single relative with melanoma) will contribute 
to the chance of an inappropriate picture of familial clustering.
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Summary 
Background: 
Dermoscopy greatly improves the clinical diagnosis of pigmented lesions. Few studies 
have investigated, however, how dermoscopy is guiding management decisions in 
everyday clinical practice. In addition, most studies have been performed in the setting of 
dermoscopy experts working in pigmented lesion clinics. 
Objectives: 
To assess the impact of dermoscopy on clinical diagnosis and management decisions for 
pigmented lesions in everyday practice of general dermatologists.
Methods:
We performed a prospective study in general dermatology clinics in community hospitals 
run by dermatologists with intermediate dermoscopy experience and expertise. Each 
clinician independently included suspicious lesions from consecutive patients. Pre-and 
postdermoscopy diagnoses and management decisions were recorded. Pathology was 
used as reference diagnosis. 
Results:
In total, 209 suspicious lesions were included in the study by 17 dermatologists. Fourteen 
lesions were histologically proven in situ or invasive malignant melanomas. Based on 
clinical diagnoses, dermoscopy improved sensitivity from 0.79 to 0.86 (P =1.0). All 14 
melanomas were intended to be excised based on naked eye examination alone, 
independent of dermoscopic evaluation. Specificity increased from 0.96 to 0.98 (P =0.22). 
Dermoscopy resulted in a 9% reduction of the number of excisions. 
Conclusions: 
Dermoscopy reduced the number of excisions, but did not improve the detection of 
melanomas. Our results suggest that in everyday clinical practice of general dermatologists 
the main contribution of dermoscopy is a reduction of unnecessary excisions.
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Introduction
 
Several studies have demonstrated that dermoscopy is better at discriminating between 
melanoma and benign pigmented lesions than naked eye examination (NEE).1–3 However, 
very few studies have investigated how dermoscopy is guiding management decisions in 
everyday clinical practice.4–7 
 The first dermoscopy studies were performed predominantly in experimental settings. 
Clinicians judged lesions based on macroscopic and dermoscopic images instead of live 
patients, study sets often contained a disproportionately high number of melanomas 
(high pretest probability) and in some studies dermoscopic images were not preceded by 
their accompanying macroscopic images.8–12
 More recent studies have evaluated dermoscopy in more realistic clinical settings.3 
Most of these studies have focused on the ability of dermoscopy to improve the clinical 
diagnosis of pigmented lesions.1–3,8–17
 
Several authors have suggested that ultimately the purpose of dermoscopy is to improve 
the ability to determine whether lesions need to undergo a biopsy procedure.5,18–21 In 
other words, dermoscopy improves the detection of melanomas only if melanomas that 
would not have been biopsied based on NEE are biopsied because of their dermoscopic 
characteristics. Dermoscopy improves the malignant ⁄benign ratio of excised lesions if it 
results in leaving benign lesions in situ that would have been biopsied based on NEE.
 
Most previous dermoscopy studies have been performed in the setting of specialized 
pigmented lesion clinics (PLCs) run by dermoscopy experts. To our knowledge there are 
no studies on the impact of dermoscopy on the clinical practice of general dermatologists 
with intermediate experience and excellence in dermoscopy. It is not unlikely that most 
(potential) dermoscopy users belong to this specific group of clinicians. The aim of this 
study was to assess prospectively the impact of dermoscopy on the clinical diagnosis and 
management of pigmented lesions in everyday clinical practice of general dermatologists. 
Materials and methods 
Participants in the study were dermatologists working in general dermatology clinics in 
community hospitals located in different parts of the Netherlands. They all had been 
performing dermoscopy for at least 6 months and had recently participated in a full-day 
dermoscopy course covering the basic dermoscopic characteristics of melanocytic and 
nonmelanocytic lesions, the ABCD rule for dermoscopy,22 pattern analysis23 and the more 
recently described (vascular) patterns and structures.24–26
 
100 | Chapter 7
For the current study they were instructed to include 20 consecutive eligible lesions of 
patients visiting their regular clinics. Patients were either newly referred (in the Dutch health 
system dermatological service is accessible only after referral by a general practitioner) or 
already under treatment at the department of the participating dermatologist. The initial 
or primary reason for patients to attend the dermatologist was irrelevant for the eligibility 
of lesions.
 Lesions were eligible if they fulfilled the following criteria: (i) they had to be suspicious 
pigmented lesions, (ii) for which the participant would normally also apply dermoscopy, 
and (iii) if a patient had more than one eligible lesion the most suspicious lesion had to be 
selected. After participants identified an eligible lesion, they first had to evaluate it on the 
basis of NEE and to record the NEE preferential diagnosis and management strategy as if 
there were no opportunity to perform dermoscopy afterwards. NEE was guided by the 
ABCDE criteria, the ugly duckling sign and symptoms reported by patients.27 Subsequently 
dermoscopy was performed and the preferential diagnosis and management strategy 
based on the combined NEE and dermoscopic evaluation were recorded (Fig. 1). 
In cases where a biopsy was performed, participants were requested to send us a copy of 
the pathology report and to indicate whether they performed the biopsy for diagnostic 
purposes or for other reasons (e.g. cosmetic). Participants were requested to add a 
description of their method of sampling, in order to check whether they had followed 
instructions to include lesions in a consecutive order. 
Data analysis 
Preferential diagnoses were categorized as ‘melanoma’ or ‘nonmelanoma’. Management 
strategies were also grouped into two categories: (i) ‘intervention’: a diagnostic (punch, 
shave or excisional) biopsy with the primary intention of histological verification and 
treatment of a possible melanoma and (ii) ‘no intervention’: follow-up, no follow-up, or an 
intervention for a nondiagnostic reason (e.g. cosmetic). For biopsied lesions histological 
diagnosis was used as the reference diagnosis. 
True positives (TP) were defined as lesions classified as melanoma, and confirmed as 
melanoma on histological examination. True negatives (TN) were defined as lesions that 
were classified as ‘nonmelanoma’, with a subsequent diagnosis other than melanoma on 
histological examination or left unbiopsied because there was no suspicion of melanoma. 
False positives (FP) were defined as lesions classified as melanoma, but not diagnosed as 
melanoma on histology, or not biopsied (after dermoscopic evaluation). False negatives 
(FN) were defined as lesions that were classified as ‘nonmelanoma’, but were diagnosed as 
melanoma on histology. Sensitivity was computed as TP ⁄(TP+FN) and specificity as TN 
⁄(TN+FP). Sensitivity and specificity were also calculated from a management perspective, 
with the clinical diagnosis ‘nonmelanoma’ being exchanged for ‘no intervention’ and the 
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clinical diagnosis ‘melanoma’ for ‘intervention’. To compare sensitivity and specificity 
before and after dermoscopy a statistical analysis was performed, using the McNemar 
test. Analyses were performed with SPSS 14.0 (SPSS, Chicago, IL, U.S.A.), and statistical 
significance was determined at a =0.05, and two-sided. 
The impact of dermoscopy on management was analysed according to the two 
management categories as defined above (‘intervention’ and ‘no intervention’), in two 
ways. The impact of dermoscopy on the detection of melanomas was calculated as the 
proportion of histologically confirmed melanomas that would not have been biopsied 
(management category: ‘intervention’) without the use of dermoscopy. In addition to this 
we calculated the proportional reduction of the number of ‘interventions’ due to 
dermoscopy. 
Figure 1  Study design 
*Pre- and post dermoscopy clinical diagnosis and management decisions were compared.
Histology / No verication  
Pre-dermoscopy*  
Clinical diagnosis 
& Management  
Post-dermoscopy*  
Clinical diagnosis 
& Management  
Naked Eye 
Examination  Dermoscopy  
Patient & Lesion selection 
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Results 
Data characteristics 
Seventeen general dermatologists with a median experience in dermoscopy of 7.5 years 
(range 6 months–14 years) participated in the study. Twelve clinicians (71%) reported a 
methodology that implied consecutive sampling. Five clinicians (29%) stated they had 
followed inclusion instructions, but gave no detailed description of their method of 
sampling. 
Participants judged a mean number of 12 lesions (range 4– 20), with a total of 209 lesions. 
Data on clinical diagnosis and management were complete for 207 (99%) and 196 lesions 
(94%), respectively. In total, 99 lesions were biopsied: 72 for diagnostic purposes, 20 for 
other reasons (e.g. cosmetic) and seven cases in which the distinction could not be made 
due to incomplete data. Among the 72 lesions that were excised for diagnostic purposes 
there were ten invasive and four in situ melanomas (Table 1). In addition, there was one 
borderline lesion, described in the histology report as ‘a dysplastic naevus with severe 
atypia, melanoma in situ not excluded’. There were no melanomas among the other 27 
biopsied lesions. 
The impact of dermoscopy on the clinical diagnosis 
Based on NEE 18 lesions were classified as melanomas (Fig. 2a). After dermoscopy only 
12 of these were still regarded to be melanomas, 10 of which were confirmed by 
histopathology. The other two lesions were diagnosed as a dysplastic naevus and a 
collision tumour consisting of a seborrhoeic keratosis (SK) and a basal cell carcinoma (BCC). 
Of the six lesions no longer classified as melanomas after dermoscopy, four were biopsied. 
Table 1   Characteristics of histologically proven melanomas diagnosed in the general 
dermatology setting
Histological type n Breslow thickness
SSM 4 0.15 mm, 0.85 mm, 0.98 mm and 2.8 mm
Mis 4 not applicable
LMM 1 not available
NM 1 1.1 mm
NOS 4 0.40 mm, 0.95 mm, 0.98 mm and 1.1 mm
Total 14
SSM, superficial spreading melanoma; Mis, melanoma in situ; LMM, lentigo maligna melanoma; NM, nodular 
melanoma; NOS, not otherwise specified
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One was diagnosed as a BCC, one as a common naevus and one as a collision tumour 
consisting of a BCC, an SK and a sebaceous adenoma. The fourth lesion, which was 
clinically diagnosed as a common naevus after dermoscopy, proved to be a malignant 
melanoma on histology (Breslow thickness 1.1 mm). The two lesions that were not 
biopsied were clinically diagnosed as lentigo maligna before dermoscopy, but were 
regarded as benign lentigines after dermoscopy and left in situ. 
After dermoscopy three lesions regarded as ‘nonmelanoma’ by NEE were reclassified as 
melanoma. Two of these were confirmed by histology (Breslow thickness 0.40 mm and an 
in situ melanoma) and one was diagnosed as a dysplastic naevus. There was one lesion 
that was incorrectly diagnosed as a dysplastic naevus, both before and after dermoscopy, 
but turned out to be a melanoma (Breslow thickness 0.95 mm). 
Sensitivity was calculated to be 0.79 (11 ⁄14) for NEE alone and 0.86 (12 ⁄14) for NEE aided 
by dermoscopy. Specificity was 0.96 (186 ⁄193) before and 0.98 (190 ⁄193) after dermoscopy 
Figure 2   The effect of dermoscopy on (A) the clinical diagnosis and (B) management 
decisions 
NEE, naked eye examination; DSC, dermoscopy; PA, pathology
NEE 
(n = 207) 
nonmelanoma 
n = 189 (91%) 
melanoma 
n = 18 (9%) 
nonmelanoma 
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n = 6 (3%) 
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n = 3 (1%) 
melanoma 






n = 1 
melanoma 
n = 10 
(n = 80) 
(n = 12) 
NEE 
(n = 196) 
no intervention 
n = 117 (60%) 
intervention 
n = 79 (40%) 
no intervention 
n = 108 (55%) 
no intervention 
n = 16 (8%) 
intervention 
n = 9 (5%) 
intervention 
n = 63 (32%) 
DSC  
DSC  
PA  melanoma 
n = 14 
PA  melanoma 
n = 0 
B: Management 
A: Clinical diagnosis 
PA  melanoma 
n = 2 (n = 3) 
PA  melanoma 
n = 1 (n = 4) 
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had been performed. Statistical analysis demonstrated that the improvements of sensitivity 
and specificity by the addition of dermoscopy were not statistically significant (P =1.0 and 
P =0.22, respectively). 
The impact of dermoscopy on management decisions 
In 13% (n = 25) of lesions management changed after dermoscopy had been performed 
(Fig. 2b): for 16 lesions (8%) a diagnostic biopsy was abandoned and for nine lesions (5%) 
a diagnostic biopsy was induced. Histological evaluation of these nine lesions demonstrated 
three common naevi, three dysplastic naevi, one benign lentigo, one congenital naevus 
and the borderline lesion that was described before. The predermoscopy management 
for this borderline lesion was noted as ‘follow-up’. Dermoscopy had no influence on the 
management of the 14 histologically confirmed melanomas, as all were intended to be 
excised (diagnostic biopsy) based on the NEE, before dermoscopy had been performed. 
Before dermoscopy 40% (79 ⁄196) of included lesions were intended to be excised 
(diagnostic biopsy). After dermoscopy 37% (72 ⁄196) of the lesions were excised. The 
malignant ⁄benign ratio of excised lesions decreased from 1 : 5.6 (14 ⁄79) before to 1:5.1 
lesions (14 ⁄72) after dermoscopy had been performed. Dermoscopy resulted in a 
reduction of the total number of diagnostic biopsies of 9% (7 ⁄79). Neither sensitivity nor 
specificity (P =1.0 and P =0.23) was increased by dermoscopy, if calculated based on 
management decisions instead of clinical diagnoses.
 
Discussion 
To our knowledge this is the first prospective study that has evaluated how dermoscopy 
influences the clinical diagnosis and is guiding management decisions made by general 
dermatologists in their routine daily practice. 
 Sensitivity increased after addition of dermoscopy to the NEE, although not 
statistically significantly. The sensitivities of NEE (0.79) and dermoscopy (0.86) in our study 
were comparable with the summary estimates of sensitivity in a recent meta-analysis of 
clinical dermoscopy studies by Vestergaard et al.3 (0.71 and 0.90, respectively).
There were two melanomas in our study that had wrongfully been classified as benign 
lesions based on NEE, but were correctly classified as melanoma due to dermoscopy. In 
one instance, however, a melanoma, correctly classified based on NEE, was reclassified as 
a benign melanocytic lesion after dermoscopy had been performed. This did not affect 
the decision to excise this particular lesion, but it illustrates the danger of false reassurance 
due to dermoscopy. 
 Dermoscopy did not improve the detection of melanomas, as all 14 melanomas were 
intended to be excised before dermoscopy was performed. Dermoscopy did, however, 
result in the decision to excise a dysplastic naevus with severe atypia, that would have 
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been left in situ to be followed up if dermoscopy had not been performed. This excision 
may have prevented the development of an invasive melanoma, but this is, of course, 
speculative.
 
Specificity slightly improved as a result of performing dermoscopy, but the difference was 
not statistically significant. Our estimates of specificity (0.96 before and 0.98 after 
dermoscopy) were higher than the summary estimates in the meta-analysis of Vestergaard 
et al.3 (0.81 and 0.90, respectively). The difference can be explained by the fact that our 
study was based on all suspicious lesions for which dermoscopy was used, including 
those that were not biopsied. Many of the studies in the meta-analysis only included 
lesions that were biopsied. Our results were comparable with a study by Stanganelli et al.14 
(specificity of 0.99 before and 1.00 after dermoscopy) that included unbiopsied lesions in 
their analyses as well.
 Dermoscopy reduced the number of excisions by 9%, which is considerably lower 
than the figure reported in other studies.4–6 In a randomized study Carli et al.4 reported 
that 38% fewer excisions were performed in the dermoscopy study arm compared with 
the NEE arm. Two prospective studies that investigated the influence of dermoscopy on 
the management of lesions preselected for excision by NEE found a reduction of the 
number of excisions of 40% and 70%.5,6
 The a priori possibility for dermoscopy to reduce the number of (unnecessary) 
excisions in our study was probably limited, due to the fact that the malignant ⁄benign 
ratio of (intended to be) excised lesions was very low before dermoscopy had been 
performed (1 : 5.6). There are a number of possible explanations for this. Most previous 
dermoscopy studies were performed in PLCs. A considerable proportion of patients seen 
at PLCs have a high a priori melanoma risk and are therefore regularly screened. As a 
consequence it is likely that the spectrum of melanomas diagnosed in general dermatology 
clinics differs from those in PLCs. Melanomas presented in general dermatology clinics 
may be in a more advanced stage, with more clear-cut clinical characteristics, making it 
easier to diagnose them based on NEE alone. This explanation is weakened, however, by 
the fact that two4,6 of the three earlier mentioned studies that reported a considerable 
reduction of the number of excisions were performed in a similar patient population as 
our study: patients who had been referred by general practitioners (in the third study the 
patient population was not described). In addition, the median Breslow thickness of 
melanomas in our study and two of the three PLC-setting studies were comparable 
(Breslow thickness was not reported in one study). An alternative explanation would be 
that general dermatologists have a higher threshold for performing biopsies of lesions, 
possibly because they are used to managing patients with a relatively low a priori 
melanoma risk, compared with the patient population seen by expert dermoscopists in 
PLCs. In addition, the management decisions made by general dermatologists, with less 
expertise in dermoscopy, are likely to be less dependent on dermoscopy. As a relatively 
106 | Chapter 7
large proportion of the lesions that were included in our study were melanomas (7%), our 
results suggest that general dermatologists perform dermoscopy only if they have a 
(relatively) high level of suspicion of melanoma. As a final note, the smaller reduction of 
the number of biopsies could not be explained by cosmetic interventions, as these were 
excluded from the analyses.
 
In conclusion, we found a comparable impact of dermoscopy on sensitivity and specificity 
in everyday clinical practice of general dermatologists as was recently reported in a 
meta-analysis based on studies that were mostly performed in expert PLC settings.3 From 
a management perspective, however, dermoscopy did not improve the detection of 
melanomas. The reduction of the number of excisions was considerably less than has 
been reported in dermoscopy-expert PLC settings. In our study in the case of one 
melanoma dermoscopy resulted in false reassurance, changing the clinical diagnosis from 
melanoma to naevus. It is of great importance that more studies are performed to evaluate 
the risk of FN due to dermoscopy in nonexpert settings. Unfortunately we had no 
histological verification of lesions that were initially regarded as melanoma, but were not 
excised because of their dermoscopic characteristics. This limited our ability to detect 
possible negative effects of dermoscopy on the detection of melanomas. More studies 
focusing not only on clinical diagnoses, but also on the management decisions, with a 
larger number of melanomas are needed, further to determine the benefits and safety of 
dermoscopy in nonexpert settings.
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Abstract
Few studies have investigated the impact of dermoscopy on the management of relatives 
from melanoma families. The objective of this study was to assess the impact of 
dermoscopy on clinical diagnosis and management decisions in high-risk familial 
melanoma patients. In a prospective study 132 consecutive patients were recruited from 
the pigmented lesions clinic of a tertiary reference centre for familial melanoma. 
Dermatologists expert in dermoscopy identified 49 suspicious pigmented lesions and 
recorded pre- and post-dermoscopy diagnoses and management decisions. Dermoscopy 
was performed in 37% of the patients. Two melanomas were identified. Dermoscopy did 
not influence sensitivity (1.0), but resulted in 42% fewer excisions, increasing specificity 
from 0.53 to 0.74 (p =0.031). Dermoscopy resulted in a large reduction in the number of 
unnecessary excisions. These results suggest that the main effect of dermoscopy in clinical 
practice for this high risk population is a significant increase in specificity, rather than 
sensitivity.
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Introduction
Incidence and, to a smaller degree, mortality rates of melanoma have increased 
dramatically in recent years.1 Between 6% and 14% of all primary cutaneous melanomas 
occur in a familial context.2 The melanoma risk for relatives from families with two or more 
melanoma patients is greatly increased. In carriers of the melanoma susceptibility gene 
CDKN2A, which is found in approximately 20–40% of melanoma families, the lifetime 
melanoma risk can be as high as 70%.3 Surveillance of these relatives is a challenging task. 
Given the mostly disappointing results of treatments for metastasized melanoma, the 
most effective way to prevent morbidity and improve survival is the early detection and 
excision of tumours. Thus, additional tools that can detect early signs of melanoma are 
valuable.
 
Dermoscopy is a non-invasive technique that enables the visualization of morphological 
structures of the skin, from the epidermis down to the superficial papillary dermis, which 
are not accessible to the naked eye. Several studies have shown that dermoscopy is better 
than naked eye examination (NEE) at discriminating melanoma from benign pigmented 
lesions.4–6 However, few studies have investigated the effect of dermoscopy in everyday 
clinical practice by studying how it guides management decisions.7–10 The beneficial 
effect of dermoscopy ultimately depends on how it improves the ability to determine 
whether lesions need to undergo biopsy.8, 11–14 Dermoscopy improves sensitivity if 
melanomas that would not have been excised based on NEE are excised because of their 
dermoscopic evaluation. Specificity improves if dermoscopy results in a decrease in the 
number of excisions of benign lesions. A management-based evaluation might give a 
different picture of dermoscopy than a diagnosis-based evaluation, because management 
is based on the differential diagnosis rather than the preferential diagnosis (which has 
been the central issue in the majority of dermoscopy studies).
The aim of this study was to investigate the impact of dermoscopy on the clinical diagnosis 
and management of pigmented lesions of relatives from melanoma families, who had a 
very high personal risk of melanoma, who visit the pigmented lesion clinic (PLC) of a 
tertiary reference centre for familial melanoma. 
Materials and Methods 
Between December 2005 and June 2007 patients from melanoma families who had a 
high personal melanoma risk were recruited from the PLC of a tertiary reference centre for 
familial melanoma (Department of Dermatology, Leiden University Medical Center) during 
their regular screening visits. Patients could be included if they fulfilled the following two 
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criteria: (i) they were a member of a melanoma family (defined as a family containing at 
least two first- or three second-degree relatives with melanoma); and (ii) they either had a 
personal history of melanoma, or were a CDKN2A mutation-carrier. 
 Dermatologists with extensive experience in dermoscopy (WB and NK) took a 
medical history and clinical examination, guided by the ABCDE criteria and the ugly 
duckling sign.15 Pigmented lesions that were regarded as clinically suspicious for 
melanoma, and for which dermoscopy would also have been used in normal daily 
practice, were analysed dermoscopically. If no suspicious lesion was found the patients’ 
next screening was scheduled, usually within one year. If more than one suspicious lesion 
was present, only the most suspicious was included. Prior to dermoscopic evaluation, the 
diagnosis and management decision based on NEE were recorded. Subsequently 
dermoscopy was performed and the diagnosis and management decision based on the 
combined NEE and dermoscopy evaluation were recorded (Fig. 1). Patients were judged in 
consensus by the two dermatologists (WB and NK). Dermoscopy was performed with a 
handheld dermatoscope on the basis of (classical) pattern analysis16, combined with more 
recently described (vascular) patterns and structures.17–19 The decision to excise a suspicious 
lesion was based on the combined NEE and dermoscopic evaluation in accordance with 
routine clinical practice. Patients with suspicious lesions that were not excised were 
followed for 12 months in order to detect melanomas that were missed at the examination 
at the time of inclusion in the study. 
Data analysis 
The proportion of high-risk patients in whom dermoscopy was performed because of a 
suspicious pigmented lesion was calculated. Pre- and post-dermoscopy preferential 
diagnoses were categorized as “melanoma” or “non-melanoma”. Management strategies 
were also grouped into two categories: (i) “intervention”: a diagnostic biopsy with the 
primary intention of histological verification and treatment of a possible melanoma; and 
(ii) “no intervention”: follow-up according to the regular surveillance programme. For 
biopsied lesions histological diagnosis was used as the reference diagnosis. In an attempt 
to exclude that melanomas were missed in the case of lesions that were left un-excised, 
follow-up data was collected one year after inclusion in the study. If the patient had not 
developed a melanoma at that time, the initial suspicious lesion was regarded as being 
“non-melanoma”. 
True positives (TP) were defined as lesions that were classified as melanoma, and confirmed 
as melanoma on histological examination. True negatives (TN) were defined as lesions 
that were classified as “non-melanoma”, with a subsequent diagnosis other than melanoma 
on histological examination or no melanoma after one year of follow-up. False positives 
(FP) were defined as lesions that were classified as melanoma, but not diagnosed as 
melanoma on histology. False negatives (FN) were defined as lesions that were classified 
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as “non-melanoma”, but were diagnosed as melanoma on histology (on inclusion or after 
one year of follow-up). Sensitivity was computed as TP/(TP+FN) and specificity as TN/
(TN+FP). Sensitivity and specificity were also calculated from a management perspective, 
with the clinical diagnosis “non-melanoma” being exchanged for the management 
strategy “no intervention”, and the clinical diagnosis “melanoma” for the management 
strategy “intervention”. To compare sensitivity and specificity before and after dermoscopy 
a statistical analysis was performed, using the McNemar test (because pre- and post-der-
moscopy data were not independent). Analyses were performed with SPSS 14.0, statistical 
significance was determined at α = 0.05, and two-sided. 
The impact of dermoscopy on management was analysed according to the two 
management categories, as defined above (“intervention” and “no intervention”), in two 
ways. The impact of dermoscopy on the detection of melanomas was calculated as the 
proportion of histologically confirmed melanomas that would not have been excised 
(management category: “intervention”) without the use of dermoscopy. In addition, we 
calculated the proportional reduction in the number of “interventions” due to dermoscopy. 
Figure 1  Study design 
*Pre- and post dermoscopy clinical diagnosis and management decisions were compared.
Histology / Follow-up (12 months)  
Pre-dermoscopy*   
Clinical diagnosis 
& Management  
Post-dermoscopy*   
Clinical diagnosis 




Suspicious lesion (n = 49) 
High risk patients from melanoma families (n = 132)  
No suspicious lesion (n = 83) 
End of study  
116 | Chapter 8
Results 
Data characteristics 
In total, 132 high-risk patients from melanoma families were included, consisting of: one 
p14ARF mutation carrier with a personal history of melanoma, four patients with a son or 
daughter with melanoma (obligatory gene carriers), 13 proven CDKN2A mutation carriers 
with a personal history of melanoma, 27 proven CDKN2A mutation carriers without a 
personal history of melanoma, and 87 patients with a personal history of melanoma (20 of 
whom had multiple primary melanomas). 
 Dermoscopy was performed in 37% of the patients (49/132). Data on clinical diagnosis 
and management was complete for all lesions. Excision with histological examination was 
performed in 14 cases. Two melanomas were diagnosed; one superficial spreading 
melanoma (SSM, Breslow-thickness 0.86 mm) and one lentigo maligna (melanoma in situ). 
The 35 patients with suspicious lesions that were not biopsied were followed for 12 
months. During follow-up one patient was diagnosed with a melanoma in situ 11 months 
after inclusion in the study. This lesion had developed in a naevus that had been changing 
over a period of 6 months according to the patient. Management had not been changed 
due to dermoscopy in this patient at the time of inclusion in the study. 
Clinical diagnosis (Fig. 2A) 
Dermoscopy did not lead to diagnosis conversions from melanoma to non-melanoma or 
non-melanoma to melanoma. Before and after dermoscopy the same seven lesions were 
considered to be melanomas. Two of these (29%) were confirmed by histology to be 
melanoma and the other five lesions were dysplastic naevi (n = 4) and a common naevus. 
Sensitivity was 1.0 (2/2) and specificity 0.89 (42/47), both for NEE alone and for NEE 
combined with dermoscopy. 
Management (Fig. 2B) 
After dermoscopy the management decisions changed in 37% of lesions (n = 18). In 14 
cases (29%) an excision was abandoned and in four cases (8%) an excision was decided 
on. These four lesions were histologically diagnosed as two dysplastic naevi and two 
common naevi. 
 Before dermoscopy an excision was intended for 49% of lesions (n = 24), compared 
with 29% (n = 14) after dermoscopy, resulting in a reduction in the total number of 
excisions by 42%. The malignant/benign ratio of excised lesions decreased from 1:12 (2/24) 
to 1:7 lesions (2/14). 
 Dermoscopy had no impact on the management of the two proven melanomas, as 
these were already intended to be excised before dermoscopy was performed. Calculations 
based on management decisions therefore did not show an increase in sensitivity. 
Specificity, however, increased significantly (p = 0.031) from 0.53 (25/47) to 0.74 (35/47).
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Discussion 
In a prospective study we investigated the impact of dermoscopy on the management of 
patients with a high a priori melanoma risk. For this purpose 132 relatives from melanoma 
families, who had a high personal melanoma risk, were included in a consecutive order. 
We recorded the proportion of patients in whom dermoscopy was performed and the 
impact of dermoscopy on clinical diagnoses and management decisions by comparing 
the evaluation of lesions by NEE with NEE followed by dermoscopy. Patients with 
suspicious lesions that were not biopsied were followed for one year after inclusion in 
order to detect false negatives.
 
In accordance with Carli et al.7 (49%) we found that, in a large proportion of patients (63%), 
dermoscopy was not performed. Familial melanoma patients are known to have increased 
numbers of (dysplastic) naevi, but the phenotype is very variable. Some of our patients 
Figure 2   The effect of dermoscopy on (A) the clinical diagnosis and (B) management 
decisions 
NEE, naked eye examination; DSC, dermoscopy; PA, pathology
NEE 
(n = 49) 
nonmelanoma 
n = 42 (86%) 
melanoma 
n = 7 (14%) 
nonmelanoma 
n = 42 (86%) 
nonmelanoma 
n = 0 
melanoma 
n = 0 
melanoma 






n = 0 
melanoma 
n = 2 
(n = 7) 
(n = 7) 
NEE 
(n = 49) 
no intervention 
n = 25 (51%) 
intervention 
n = 24 (49%) 
no intervention 
n = 21 (43%) 
no intervention 
n = 14 (29%) 
intervention 
n = 4 (8%) 
intervention 
n = 10 (20%) 
DSC  
DSC  
PA  melanoma 
n = 2 
PA  melanoma 
n = 0 
B: Management 
A: Clinical diagnosis 
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had hardly any naevi and many had only a few. Moreover, patients were under long-term 
surveillance, and many (suspicious) lesions had already been removed in the past.
Dermoscopy reduced the number of excisions considerably (42%), which is in agreement 
with other studies.7–9 In a randomized study Carli et al.7 found that 38% less excisions were 
performed in the dermoscopy study-arm compared with the NEE arm. Two prospective 
studies that investigated the influence of dermoscopy on the management of lesions 
pre-selected for excision by NEE, found a reduction in the number of excisions of 40% and 
70%. 8, 9
 Dermoscopy had no impact on the clinical diagnosis or management of the two 
histologically proven melanomas and, as a consequence, did not improve sensitivity. 
Although specificity was not improved by dermoscopy from a clinical diagnosis 
perspective, it was significantly improved from a management perspective (0.53 before, 
0.74 after dermoscopy), without a decrease in sensitivity, as no melanomas were missed 
due to the reduction in the number of excisions. This can be explained by the fact that, in 
accordance with other studies20, 21, a considerable proportion of the lesions that were 
clinically judged to be benign (preferential diagnosis), were nevertheless regarded as 
suspicious enough to be excised (based on their differential diagnosis). For such lesions 
dermoscopy did not affect the clinical diagnosis, but had great influence on the selected 
management strategy; hence the improvement in specificity.
 
In a meta-analysis of studies comparing dermoscopy and NEE of suspicious pigmented 
lesions in a clinical setting, Vestergaard et al.6 found that dermoscopy improved sensitivity 
significantly, but had no significant effect on specificity. Our results suggest that, from a 
management perspective, dermoscopy rather does the opposite: improving specificity 
rather than sensitivity. Of course, our study was limited by the fact that only two 
melanomas were diagnosed, but we recently reported similar trends in a larger study in 
the setting of general dermatologists working in general dermatology clinics.22
 Dermatologists (specialized in) judging pigmented lesions seem to have developed 
considerable skills in making a final decision from patient history, clinical picture, 
differential-, comparative-, pattern-recognition and “gut”-feeling23, which may limit the 
extent to which dermoscopy contributes to identification of lesions suspicious for 
melanoma by this group of specialists. However, the use of dermoscopy over the past 20 
years may have sharpened the NEE of pigmented lesions, and taught dermatologists to 
look at a pigmented lesion in a more detailed fashion.
In conclusion, dermoscopy was not performed in the majority of patients from a regularly 
screened, high melanoma risk patient population. Dermoscopy reduced the number of 
excisions considerably, and (from a management perspective) increased specificity 
significantly, without compromising sensitivity. However, dermoscopy did not improve 
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the detection of melanomas. Studies based on clinical diagnosis may overestimate the 
impact of dermoscopy on the ability to detect melanomas, while underestimating its 
ability to reduce the number of unnecessary excisions. Future studies with higher numbers 
of patients are needed to determine the impact of dermoscopy in daily practice, by 
investigating the impact of dermoscopy on management decisions. 
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Summary and Discussion
Introduction
Familial susceptibility is the strongest risk factor (in terms of effect size) for melanoma, and 
is associated with a very high life-time melanoma risk, especially in the context of the 
high-penetrance melanoma susceptibility genes CDKN2A, and CDK4. Early melanomas 
can be cured by an excision with proper resection margins, but prognosis is grim for 
advanced disease. For these reasons, surveillance of melanoma families has been widely 
advocated. The studies presented in this thesis focused on 3 related issues: 1. the clinical 
and histological characteristics of melanoma (patients) from melanoma families with a 
pathogenic germline mutation in CDKN2A; 2. the effectiveness and yield of surveillance of 
melanoma families with different CDKN2A mutation status and  family characteristics, and 
3. the impact of dermoscopy on the management of suspicious lesions in the context of 
melanoma surveillance. In this concluding chapter, our results will be discussed jointly and 
in the context of (recent) medical literature.
Part I:  Clinical and histological characteristics of melanoma in CDKN2A 
mutated families.
Several studies have demonstrated that melanoma patients from melanoma families have 
a different clinical presentation than melanoma patients from the general population. In 
chapter 2 we verified and substantiated these differences by comparing the clinical and 
histological characteristics of 182 patients with 429 CMM from families with a germline 
mutation in CDKN2A, to a large control population from the Leiden population based 
cancer registry (7512 patients with 7842 CMM). 
 We confirmed that melanoma patients from CDKN2A mutated families have a young 
age of onset and a very high risk of multiple primary melanomas (MPM). We found a mean 
age of diagnosis of 39.0 years, which is 15 years younger than the general population. 
Concerning MPM we reported for the first time a difference in concordance with regard to 
the body site of the first and second melanoma. Where a concordance was seen in MPM 
patients from the general population, concordance was absent in MPM patients from 
CDKN2A mutated families. These findings are all in accordance with the high melanoma 
susceptibility in CDKN2A mutated families, and emphasize the importance of regular skin 
examinations, starting at a young age and involving the whole skin.
In accordance with earlier studies we found that a relatively high proportion of superficial 
spreading (≈ 90%) and relatively few lentigo maligna type melanomas (2%) and nodular 
melanomas (8%) are diagnosed in these families. Contrary to other studies that reported 
an absence of acrolentiginous melanomas (ALM) in melanoma families, the proportion of 
ALM in our dataset was similar to the general population.1,2 
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 We found that relatively few melanomas from CDKN2A mutated families were located 
in the head and neck region, but the difference was not statistically significant in a 
multivariate analysis. However, melanomas that were located in the head and neck region, 
were diagnosed at a relatively young age compared to melanomas localized elsewhere 
on the body, whereas, in the general population, melanomas in the head and neck region 
were diagnosed at a relatively older age compared to melanomas elsewhere on the body. 
This difference persisted if lentigo maligna melanomas were excluded from the analysis.
Both epidemiological and genetic data suggest that melanoma is a (clinical, histological, 
epidemiological and molecular) heterogeneous disease, and different pathways to 
melanoma genesis have been proposed.3 As described in chapter 2 our results with 
regards to the clinical and histological characteristics of melanoma (patients) from families 
with a germline mutation in CDKN2A suggest that their distribution along these different 
pathways differs from the general population. From the perspective of the divergent 
pathway model by Whiteman at all, CDKN2A mutated families tend to follow the nevus 
pathway, which is associated with a phenotype of multiple nevi and intermittent sun 
exposure.4 This supports the notion that prevention of high intermittent sun exposure 
and sunburn is of great significance within this population. Future studies have to clarify 
to what extent the natural development and prognosis of melanomas in families with 
CDKN2A germline mutations differ from sporadic melanomas, as well as the potential 
implications for preventive and treatment strategies.
Part II: Management of melanoma families
Effectiveness of surveillance
Only few studies have investigated the effectiveness of surveillance of melanoma 
families.5-8 We estimated the effect of surveillance on tumour Breslow thickness in: 1. a 
retrospective data-set of 226 melanomas from relatives of 37 CDKN2A mutated families 
that were under surveillance at the LUMC pigmented lesion clinic (chapter 3), and 2. 
Fifty-one prospectively detected melanomas in 37 patients among 450 members of 72 
melanoma families that were registered at the Netherlands Foundation for the Detection 
of Hereditary Tumors (NFDHT) and under surveillance throughout the Netherlands 
(chapter 4).
In accordance with previous studies we found that melanomas detected in patients under 
surveillance (surveillance melanomas) had a significantly thinner Breslow thickness than 
index melanomas (i.e. the first melanoma of the first two family members diagnosed with 
melanomas). In both studies the median thickness of surveillance melanomas was 0.50 
mm, which is comparable to earlier studies.5,7,8 On average, index melanomas were 
approximately 1.5 times as thick as surveillance melanomas. The proportion of surveillance 
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melanomas with a Breslow thickness > 1.0 mm, was 11% and 22% in chapter 3 and 4 
respectively. In the LUMC PLC setting surveillance melanomas were estimated to be 3 
times less likely to have a Breslow thickness > 1.0 mm compared to index melanomas. In 
chapter 4 no statistically significant difference was found with respect to the proportion 
of melanomas with a Breslow thickness > 1.0 mm in the surveillance and index group, but 
significance may not have been reached due to lack of power (estimate of the odds ratio 
was 2.5, which is comparable to chapter 3). We did report in chapter 4 that none of the 37 
patients, who were diagnosed with their first melanoma during surveillance, had died 
after a median follow-up of 4.2 years since diagnosis.
 Our findings support the notion from previous studies that surveillance results in 
earlier detection of melanomas and as such, is likely to improve survival of patients from 
melanoma families. Acknowledging the limitations of a direct comparison of the two 
datasets, our studies suggest that surveillance in the setting of a tertiary familial melanoma 
PLC clinic (chapter 4) was more effective in reducing the proportion of thick melanomas 
(11% of surveillance melanomas with Breslow thickness > 1.0 mm) than the setting of 
general dermatology departments (22% of surveillance melanomas with Breslow thickness 
> 1.0 mm, chapter 5). Effectiveness of  surveillance of the highest risk populations may 
benefit from centralization to highly specialized clinics.
Surveillance interval
There is very little data on the optimal length of the interval between two skin examinations 
for melanoma. In Chapter 3 we report that the majority of surveillance melanomas were 
detected within 6 months since the previous surveillance skin examination. The current 
2012 Dutch melanoma guideline recommends patients should be seen at least annually.9 
In order to determine the appropriate surveillance interval it is important to know the 
natural history of melanoma. Several studies have attempted to approximate the 
melanoma growth rate based on patients recall of the moment the lesion was first noticed 
or started changing. Even though this approach has considerable theoretical as well as 
practical  limitations, it was demonstrated that (this measurement of) growth rate is 
prognostic of survival, independent of Breslow thickness.10-12 Consequently, three types of 
melanomas have been defined: slow growth melanoma (< 0.1 mm/month), intermediate 
growth (0.1 – 0.49 mm / month) and fast-growing melanoma (≥ 0.5 mm/month). It was 
reported that all three types represent approximately one-third of CMM.13 This is in line 
with the fact that most melanomas in chapter 3 were detected within 6 months since the 
previous skin examination, and suggest that, if one is to advance the detection of those 
melanomas that are most likely to have an unfavourable outcome, surveillance may need 
to be performed at least biannually.
 However, we found no correlation between tumour thickness and the length of the 
surveillance interval for melanomas detected within 24 months since the previous skin 
examination. A possible explanation for this contra-intuitive finding may be that it is more 
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likely that patients will present intermediate and fast growing melanomas to their 
physician in between their regular surveillance appointments, as these melanomas are 
more noticeable than slow growing melanomas. In our study (chapter 3) 20% of 
surveillance melanomas were so-called interval tumors, i.e. detected in between regular 
surveillance visits. The majority of these were identified by patients themselves, in an early 
stage. Patients that participate in our surveillance program, are instructed to perform 
monthly skin self-examinations (SSE). The performance of SSE has been demonstrated to 
be associated with detection of melanomas in an early stage, and improved melanoma 
survival, and is therefore a valuable addition to surveillance by physicians.14
Compliance
In chapter 3 we studied adherence to surveillance recommendations at the time of 
melanoma diagnosis. Noncompliance was defined as a diagnosis of melanoma later than 
2 months after the recommended surveillance date. We found that 20% of surveillance 
melanomas were detected in noncompliant patients. The median surveillance interval at 
the time of diagnosis was 24 months. When we limited the analysis to individuals who 
were diagnosed with their first melanoma  the proportion of noncompliant patients was 
46%. These results are in accordance with two earlier studies, that reported that adherence 
to surveillance recommendations was approximately 50% among members of CDKN2A 
mutated families, and higher for individuals with a history of melanoma compared to 
individuals without a history of melanoma.15,16 
 We found that melanomas of patients that were noncompliant, were 5-times more 
likely to have a tumor thickness > 0.75 mm compared to melanomas of compliant patients.
These findings are of great concern because they suggest that current health-education 
to high-risk patients is ineffective in communicating the importance of regular surveillance, 
particularly for individuals without a personal history of melanoma. Several interventions 
to improve compliance have been described; these include: 1. clear recommendations on 
surveillance, 2. psycho-education, 3. skill-based training (related to SSE), 4. time and space 
for individuals to explore and express their feelings and concerns about melanoma with a 
caring and attentive professional, 5. genetic testing, 6. shortening surveillance intervals.15 
A more detailed description of the management of health behavioral change processes is 
beyond the scope of this chapter.
Yield of surveillance
Members of melanoma families are invited to participate in surveillance based on the 
assessment of their melanoma risk. Few studies have evaluated the yield of surveillance in 
relation to patient and family characteristics on which risk assessment is based. In chapters 
4 and 5 we assessed the yield of surveillance in family members with different personal 
and family characteristics. Additional data on melanoma detection rates came from 
chapters 2 and 8.
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History of melanoma
In accordance with an earlier study, we found that family members with a history of 
melanoma have a considerable higher melanoma detection rate then their first degree 
relatives (HR 3.9, chapter 4). 17  As melanoma patients are probable carriers of the genetic 
risk factor in their family, it was anticipated that this subpopulation is at a particularly high 
risk of developing (additional) melanomas. In chapter 2 we performed a quantitative 
analysis of the risk to be diagnosed with a second melanoma in (single) melanoma 
patients from families with the p16-Leiden mutation, and found the 5 and 10 year 
cumulative melanoma incidence to be 23.4% and 34.8% respectively. This is considerably 
higher than the risk of second melanoma in the general population. We found that the 
increased risk was age dependent, with a HR of 15.8 for patients with melanoma diagnosed 
before the age of 40 years and 7.5 for patients diagnosed above age of 40 years respectively. 
 Both in chapter 2 and 4 we computed the occurrence of only the first subsequent 
melanoma for each patient. As melanoma counts as high as 19 (chapter 2) have been 
reported, the overall melanoma detection rate in melanoma patients is expected to be 
considerable higher. 
CDKN2A mutation status
In chapter 4 we compared the melanoma detection rate in families with different 
CDKN2A mutation status. In a multivariate analysis we demonstrated that the melanoma 
risk in p16-Leiden mutated families was statistically significant higher than in CDKN2A 
wild-type families, independent of the families’ number of melanoma patients and 
youngest age of melanoma diagnosis, with a HR of 3.6. Given the fact that CDKN2A (and 
CDK4) is the only known high risk melanoma susceptibility genes, it was expected that 
families with these mutations are at a particularly high melanoma risk. It should be noted 
however that CDKN2A/CDK4 wild-type families, are very heterogenic. As discussed in the 
introduction, melanoma risk in the majority of these families is probably attributable to (a 
combination of)  low (e.g. MC1R) and moderate (e.g. MITF) risk modifier genes, and 
presumably to some extent environmental, as well as behavioral aspects.18,19 It cannot be 
excluded however that rare high penetrance genes play a role in a small proportion of 
these families. It is likely that such families have similar characteristics as CDKN2A mutated 
families, i.e. larger numbers of melanoma patients, young age of diagnosis and patients 
with multiple melanomas. In chapter 4 we found a borderline non-significant difference 
in melanoma detection rate between families with 2 melanoma patients and families with 
3 or more melanoma patients (HR 2.2, 95% CI: 0.9 – 5.0), which is in accordance with the 
notion that number of affected relatives is positively correlated with melanoma risk.
Second degree relatives
In the Netherlands, historically all first and second degree relatives from melanoma 
families have been recommended to undergo regular skin examinations. The subject of 
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surveillance of second degree relatives has received hardly any attention in the medical 
literature and foreign melanoma guidelines. In chapter 5 we performed a study to 
investigate the yield of surveillance of second degree relatives from P16-Leiden families. 
We found a melanoma incidence rate of 2.2 / 1000 person years if all available data on 
second degree relatives was included in the analysis. In a sub-analysis of second degree 
relatives under surveillance we found a melanoma detection rate of 8.5 / 1000 person 
years. Differences in these outcome are most likely related to selection bias, i.e. persons at 
high risk were more likely to participate in surveillance, difference in age distribution and 
possible under-reporting and under-detection in unscreened individuals. Standardized 
morbidity ratio for second degree relatives compared to the general population was 12.9. 
Risk stratification
As was discussed in the introduction, the surveillance recommendations in the 2005 
melanoma guidelines were independent of CDKN2A (and CDK4) mutation status and 
family characteristics. Based on Chapter 2, 4, 5 (and 8) figure 1 proposes a risk stratification 
diagram for members of melanoma families.
Our studies were restricted to families with the p16-Leiden mutation in CDKN2A. Although 
melanoma risk may vary to some extent, previous studies suggest that similar estimations 
probably apply to other pathogenic mutations in CDKN2A, as well as CDK4 mutations.20-22 
 It is important to stress that the proposed risk categorization has its limitations. 
Families with CDKN2A (and CDK4) wild-type or unknown mutation status are very 
heterogeneous. The majority of these families will have a considerable lower melanoma 
risk than CDKN2A mutated families, but in some families yet unknown high risk 
susceptibility genes may be present. As described above, family characteristics can 
provide additional information that may justify an upgrade to a higher risk category (this 
issue will be addressed in more detail below, where its practical implications are discussed).
 The NNS in figure 1 are based on chapter 5 in which melanoma incidence was 
calculated in two ways. The lower NNS represent actual NNS in the LUMC PLC surveillance 
program. The higher NNS were based on calculations in which patients that were not 
under surveillance in this institution, were included as well. We expect actual NNS to be 
nearer to the lower margin.
Management recommendations
Based on this thesis a number of recommendations can be given concerning the 
management of melanoma families. Our data from chapter 3 and 4 is in accordance with 
previous data that surveillance results in early diagnosis and a reduction in the proportion 
of melanomas with a Breslow thickness > 1mm. This finding supports the notion that 
surveillance should be recommended to family members at a significant risk of melanoma. 
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 The data from chapter 4 indicate that families with pathogenic mutations in CDKN2A 
have a considerable higher melanoma risk than CDKN2A wild-type families. Melanoma 
patients from these families have a very high risk of multiple melanoma, the majority of 
which (≈75%) were diagnosed in the first 10 years after diagnosis. Intensified surveillance 
of these relatives, at least during the first 10 to 15 years after melanoma diagnosis, is therefore 
recommendable. As we found (chapter 2) that the majority of melanomas were detectable 
within 6 months since the previous skin examination, at least biannual surveillance of this 
highest risk population should be considered. Given the fact that we did not find a 
correlation between Breslow thickness and surveillance interval, a switch from annual 
(2005 melanoma guideline) to biannual surveillance in this risk population, may be 
introduced in the context of a randomized prospective study. We estimated (chapter 5) 
Figure 1   Proposed risk categories based on melanoma detection rates during 
surveillance of melanoma patients, first- and second degree relatives from 
mutated and wildtype CDKN2A families
NNS = Numbers Needed to Screen to detect one melanoma (numbers based on chapter 5)
1  Risk categories are approximations based on hazard ratio’s calculated in chapter 4 and 5: HR (melanoma patients 
versus first degree relatives) ≈ 4, HR (CDKN2A mutated versus CDKN2A wild-type families) ≈ 3.5, and HR (CDKN2A 
mutated first degree relatives versus second degree relatives) ≈ 2.5 – 5.0. NNS give an indication of the quantitative risk.
2  Our studies were only conducted in families with the P16-Leiden mutation, the predominant CDKN2A mutation in the 
Netherlands.
3  CDKN2A/CDK4 wild-type families are heterogeneous; dotted lines are used to emphasize the variance in melanoma 
risk. Based on chapter 4, risk of melanoma (recurrence) in families with ≥ 3 melanoma patients is expected to be higher 
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that the melanoma risk of second degree relatives from CDKN2A mutated families is 
considerable higher than the risk of the general population (Standerdized Morbidity Ratio 
≈ 13). Based on results from chapter 4 and 5, we estimate that melanoma risk of second 
degree relatives from CDKN2A mutated families is comparable to melanoma risk of first 
degree relatives from CDKN2A wild-type families. These findings support the continuation 
of offering surveillance to second degree relatives from these very high melanoma risk 
families.
 Families with an unknown CDKN2A mutation status took an intermediate melanoma 
risk position, which is likely attributable to a proportion of these families having a mutation 
in CDKN2A or CDK4. Genetic testing of these families is desirable in order to estimate 
melanoma risks, and facilitation of adequate surveillance recommendations. Because 
CDKN2A wild-type families are heterogeneous, melanoma risk estimation in these families 
should be accompanied by a critical appraisal of family characteristics. Chapter 4 gives 
support to the notion that the number of melanoma patients in a family is positively 
correlated with melanoma risk in these families. With regards to the classification in figure 
1, it should be considered to “upgrade” CDKN2A wild-type families with many affected 
relatives to a higher risk category. Melanoma risk of first degree relatives from families with 
only two affected relatives, and with a single melanoma, diagnosed at an older age (e.g. 
> 50 years) is expected to be relatively low, but still higher than the general population. 
The yield of surveillance of second degree relatives from (the majority of) CDKN2A 
wild-type families is expected to be very small, and cessation of the offering of surveillance 
to this population should be considered.
 In chapter 3 we reported that interval melanomas detected by patients were 
diagnosed after a median surveillance interval of 5 months and had a favorable tumor 
thickness. These findings supports the growing evidence that SSE is a key factor in 
effective melanoma surveillance. Instruction to perform monthly SSE should therefore be 
given to all patients. Formalization of these instructions may enhance patients adherence 
to SSE recommendations.
 We found that noncompliance with the surveillance program was considerable, 
being close to 50% at the time of melanoma diagnosis for patients without a history of 
melanoma. Noncompliance was associated with thicker melanomas and is therefore a 
considerable threat to the effectiveness of surveillance. Compliance should therefore be 
one of the targets of surveillance and strategies to improve compliance should be 
developed.
 In table 1, age at diagnosis (in percentiles) of the first melanoma in members of 
melanoma families with different CDKN2A mutation status as were found in chapter 2, 4 
and 5 are presented. 
Table 1 shows that approximately 80% of melanomas were diagnosed before age 50 years, and 
90% of melanomas were diagnosed before age 60 years. These findings suggest that 
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upper age limits on (intensified) surveillance, especially in patients with an intermediate risk, 
may improve the cost-effectiveness of surveillance, without considerable loss of effectiveness.
Over-diagnosis
Over-diagnosis of melanomas has been a recurring point of discussion. It became an issue 
as a result of the observation that, whereas melanoma incidence has been increasing 
considerably over the last decades, mortality has increased relatively little. Some have 
argued that the increase of melanoma incidence is largely attributable to indolent 
melanocytic tumors, that are diagnosed as a result of increasing attention and screening 
for melanoma.
 In chapter 6 we report an observation related to over-diagnosis/misclassification in 
10 CDKN2A wild-type members of melanoma families with the p16-Leiden mutation. In 
this group 73% (7 in situ and one invasive) of 11 melanocytic lesions that were initially 
classified as melanomas, were reclassified as benign lesions after histological revision. This 
implied that 7 out of 10 of these CDKN2A wild-type family members were unnecessarily 
burdened with a diagnosis of melanoma. 
Table 1   Age of diagnosis of first melanoma in members of melanoma families (based 
on studies 2, 4 and 5)
Percentiles1 Age of diagnosis (first melanoma)











Minimum 11.7 15.6 16.5 16.4 19.7
10 21,7 20,5 21,6 24,3 25,7
20 27,2 23,8 26,0 29,9 29,8
30 31,7 27,6 28,5 35,9 33,7
40 35,5 35,0 32,6 38,6 38,4
50 38,6 37,8 38,1 42,5 43,3
60 41,1 40,0 41,0 46,7 46,5
70 45,1 43,4 45,1 49,1 49,6
80 50,5 51,5 49,2 54,4 54,3
90 57,5 60,4 56,4 61,0 59,7
Maximum 72.3 72.3 69.3 78.2 75.6
1  Percentiles represent the proportion of melanoma patients that were diagnosed with melanoma at the given 
age in the right columns; e.g. in Chapter 2, 40% of melanoma patients were diagnosed with their melanoma at 
age ≤ 35.5 years.
2 All cases in chapter 5 are included in chapter 2 as well.
3 These are all incident cases.
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 This observation illustrates that if populations with a low a priori melanoma risk 
participate in surveillance, the positive predictive value of a histological diagnosis of 
melanoma decreases. In order to limit misclassification of benign lesions as melanoma 
(false positives), it is important to make an adequate selection of risk populations for 
surveillance. In addition, this finding challenges the reported increased melanoma 
incidence among mutation negative relatives, which has caused doubt on the value of 
genetic testing for mutations in CDKN2A.23
Table 2   Recommendations
Recommendations for the development of surveillance strategies for melanoma families *
1. Intensified surveillance of melanoma patients from (CDKN2A mutated) melanoma families, at 
least up to 10 years after melanoma diagnosis is recommended. (Chapter 2, 4)
2. Genetic testing helps identifying those families and individuals at highest risk of melanoma. 
Melanoma family members should therefore be encouraged to be tested (i.e. melanoma 
patients from families with unknown CDKN2A mutation status and first degree relatives in case 
of families with a pathogenic CDKN2A mutation). (Chapter 2, 4, 5 and 6) 
3. Surveillance should start at an early age (preferably before age 15 years). Discontinuation of 
surveillance above age 60 years may improve the cost-effectiveness of surveillance, without 
considerable loss of effectiveness, especially in case of family members without a history of 
melanoma from intermediate to low risk families. (Chapter 2,4 and 5)
4. Given the fact that most melanomas in our studies were detected within 6 months since the 
previous skin-examination, biannual skin-examinations should be considered, especially for 
those at highest risk of melanoma (i.e. melanoma patients and proven CDKN2A mutation 
carriers). (Chapter 3)
5. The favourable Breslow thickness of interval melanomas, underlines the importance of health 
education for melanoma family members concerning the signs of melanoma and  skin self-
examination. (Chapter 3)
6. Noncompliance has a considerable impact on the effectiveness of surveillance. Strategies 
need to be developed to improve patients' compliance. (Chapter 3)
7. The probability of melanoma detection in CDKN2A mutated families is higher than in (most) 
CDKN2A wildtype families. CDKN2A mutated families therefore require more stringent 
surveillance strategies. (chapter 4)
8. Surveillance of second degree relatives should be considered for CDKN2A mutated families, 
but the yield of surveillance of second degree relatives from CDKN2A/CDK4 wildtype families 
appears to be very limited, especially in case of few affected relatives. (chapter 4 and 5)
9. The use of dermoscopy in the surveillance of melanoma families reduces the number of 
unnecessary excisions. Dermoscopy is therefore likely to reduce the burden of surveillance, 
improve cost-effectiveness and decrease the risk of overdiagnosis. The use of dermoscopy is 
therefore recommended. (chapter 6 and 7)
*  Except for recommendation 6, all recommendations in this table are (fully or in part) reflected in the ‘new’ 2012 
Dutch melanoma guideline.
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Part III: Impact of dermoscopy on clinical practice
Several meta-analysis have concluded that dermoscopy improves the diagnostic accuracy 
of the clinical diagnosis of melanoma with the unaided eye.24-26 We investigated how this 
is reflected in the impact of dermoscopy on management in two different clinical settings: 
1. The specialized pigmented lesion clinic of the LUMC in which two dermoscopy 
experts identified and evaluated in consensus 49 suspicious lesions including 2 
melanomas, in 132 consecutive FAMMM patients with a history of melanoma and/or 
a pathogenic mutation in CDKN2A (chapter 8).
2. The general dermatology clinics of 17 dermatologists, that evaluated a total of 209 
suspicious pigmented lesions, including 14 melanomas (chapter 7). 
The impact of dermoscopy on clinical diagnosis
In neither of the clinical settings the addition of dermoscopy to naked eye evaluation 
(NEE) resulted in a statistically significant improvement of sensitivity or specificity of the 
clinical diagnosis of melanoma with the unaided eye. However, we did find an (not 
statistically significant) increase in sensitivity from 0.79 to 0.86 and in specificity from 0.96 
to 0.98 for dermatologists working in general dermatology clinics (chapter 7), which is 
very similar to a meta-analysis of dermoscopy studies performed in a clinical setting, 
reporting that dermoscopy improves sensitivity rather than specificity.26 
 In the expert dermoscopists / familial melanoma surveillance setting, dermoscopy 
did not result in an improvement of sensitivity (1.0) or specificity (0.89) (chapter 8). We 
believe that this finding is related to the fact that only 49 suspicious lesions with only 2 
melanomas could be included in our study, as suspicious lesions necessitating the use of 
dermoscopy were detected in only 37% of the 132 patients that were recruited. This could 
be attributed to the highly variable nevus phenotype of familial melanoma patients (gene 
carriers can have very few (atypical) nevi), and the fact that patients were under regular 
surveillance, implicating that (suspicious) lesions may have already been removed in the 
past.  
The impact of dermoscopy on clinical practice
Dermoscopy was associated with a considerable reduction in the number of lesions that 
were excised, both in the expert dermoscopists / familial melanoma surveillance setting 
(42% reduction, statistically significant) and general dermatology clinics setting (9%, not 
statistically significant) (chapter 7 & 8). Our findings on the impact of dermoscopy on 
management in the expert dermoscopists setting are very similar to the only randomized 
controlled trial in a (dermoscopy expert) dermatologists setting that has ever been 
conducted, reporting a 38% reduction in excisions.27 The reduction of excisions was 
considerably lower in the general dermatologists setting. Some confirmation of this 
findings comes from two recent studies. First, a study investigating the impact of 
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dermoscopy on management of pigmented lesions by general dermatologists based on 
photographic images, found dermoscopy actually resulted in a slight increase in the 
intention to excise lesions.28 An important limitation of this study however was the fact 
that it only included excised lesions. Second, an international study reported that between 
1998 and 2007 the number needed to excise to detect one melanoma almost halved in 
specialised clinical settings, but remained unchanged in non-specialised clinical settings 
(including general dermatologists and general practitioners).29 The authors of this study 
suggested that the difference is most likely related to differences in the uptake of 
dermoscopy.25 Our results suggest that, in addition to differences in the uptake of 
dermoscopy, dermoscopy may be less effective in reducing the numbers needed to 
excise in the hands of non-expert dermoscopists and/or in the patient population setting 
of non-specialised clinics. 
In summery chapter 7 and 8 suggest that the main effect of dermoscopy in the dermoscopy 
expert / familial melanoma surveillance setting, was a significant improvement of 
specificity (from a management, but not from a clinical diagnosis standpoint),  and a 
decreased burden of unnecessary excision. Dermoscopy is therefore likely to improve the 
cost effectiveness of familial melanoma surveillance, and in addition may decrease the risk 
of ‘overdiagnosis’. The impact of dermoscopy in the general dermatology setting was 
considerably smaller, and no statistically significant improvement of sensitivity or 
specificity were noticed. Possible explanations for the differences between the two clinical 
settings may be related to the degree of dermoscopy expertise as well as differences in 
the population under study. Differences in lesion ascertainment between the two clinical 
settings may have resulted in an underestimation of the reduction of the number of 
excisions in the general dermatology setting.
An important issue that has been suggested before, but has now been clearly 
demonstrated in our studies, is the fact that prior studies that evaluated dermoscopy from 
a clinical diagnosis perspective, give an inaccurate picture of its impact in clinical practice. 
The just mentioned meta-analysis by Vestergaard et al. concluded that dermoscopy rather 
improves sensitivity than specificity and the promotion of dermoscopy has benefitted 
considerably from the proclamation that it advances melanoma diagnosis.26 Our studies 
confirm an earlier randomized controlled trial, that dermoscopy primarily results in the 
reduction of excisions. Our studies were considerably limited in their ability to detect an 
improvement of sensitivity due to the small number of melanomas. Still, it appears logical 
that dermoscopy predominantly reduces the proportion of excisions (i.e. improve 
specificity rather/more than sensitivity), as the majority of clinicians use dermoscopy 
predominantly for the evaluation of lesions that have been judged to be suspicious by 
naked eye examination. Dermoscopy can be applied in several ways however (table 3); 
first of all dermoscopic evaluation can be performed only once or sequentially in case of 
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dermoscopic follow-up; secondly lesion selection for dermoscopic evaluation can be 
limited to lesions that appear suspicious by NEE evaluation, or include lesions that are 
regarded inconspicuous by NEE. The impact of dermoscopy on sensitivity and specificity 
are expected to be highly dependent on the way in which it is used. This aspect has had 
limited attention in the literature so far.
If the primary effect of dermoscopy in clinical practice is a reduction of the number of 
excisions, this implies that, as an effect, sensitivity could be compromised. This danger is 
illustrated in chapter 7 by a histologically proven melanoma that was diagnosed as 
melanoma prior to dermoscopy, but as a benign lesion after dermoscopy. In this case the 
change in clinical diagnosis had no impact on the decision to excise this particular lesion, 
but it clearly illustrates the possible drawback of dermoscopy. In accordance with a few 
other studies, we found (chapter 8) that the increase of specificity does not result in a loss 
of sensitivity in case of dermoscopy experts.27,30,31 This cannot be stated with certainty for 
the non-expert dermatologists because we had no follow-up data with respect to lesions 
that were not excised as a result of dermoscopy. Data on the safety of dermoscopy 
performed by non-expert dermoscopists is limited.25,32 This issue, as well as the issue 
concerning the amount of training that is necessary to develop optimal dermoscopy skills 
(reflected in its impact on lesion management), may be a subject of future studies.

















* method of dermoscopy in chapter 8 & 9, as well as the majority of studies evaluating dermoscopy.
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Summary and concluding remarks
In the first part of this thesis it was shown that clinical and histological characteristics of 
melanoma (patients) from CDKN2A mutated families differ from the general population in 
several ways. As evidence on the existence of distinct melanoma subtypes is increasing, 
our data suggest that there may be overrepresentation of certain subtype(s) in these 
families, which may impact future preventive and treatment strategies.
 In the second part of this thesis we confirmed previous reports that surveillance of 
melanoma families results in early diagnosis. We showed that noncompliance is a major 
concern, especially for family members without a history of melanoma. The favourable 
tumour stage of self-detected (interval) melanomas and the observation that the majority 
of melanomas were detected within 6 months since the previous skin-examination stress 
the importance of monthly self-examination as a key element in successful melanoma 
surveillance. Based on our data we propose a risk classification system for members of 
melanoma families, that supports the development of a more tailored and cost-effective 
surveillance program. Our findings support the surveillance of second degree relatives 
from CDKN2A mutated families. Further studies are needed in order to optimize current 
surveillance strategies, including optimal surveillance intervals and to facilitate the 
assessment of melanoma risk in CDKN2A wild-type families.
 In the third part of this thesis we demonstrated that dermoscopy in the context of an 
expert / high melanoma risk PLC setting, resulted in a considerable reduction of 
unnecessary excisions. Dermoscopy is therefore likely to reduce the burden of surveillance, 
improve cost-effectiveness and decreases the risk of overdiagnosis. The impact of 
dermoscopy on management in the expert PLC setting was considerably higher than in 
the general dermatology setting. These findings confirm and clarify the value of 
dermoscopy for the PLC setting and suggest that more studies are needed to clarify and 
optimize the role of dermoscopy in a non-expert dermoscopist, general dermatology 
settings. 
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Het melanoom van de huid is een kwaadaardige tumor uitgaande van de pigmentcellen 
in de huid. Als er in een familie sprake is van tenminste twee eerstegraads verwanten 
(ouders, broers, zussen en kinderen) met een melanoom, of drie melanomen bij tweede - 
graads verwanten uit één familie, wordt gesproken van familiair melanoom.1 In ongeveer 
40% van deze families wordt een pathogene kiembaanmutatie in het CDKN2A gen 
gevonden. CDKN2A mutatiedragers hebben een sterk verhoogd risico (ca. 67%) om 
tijdens hun leven één of meer melanomen te ontwikkelen. De meest voorkomende 
pathogene CDKN2A mutatie in Nederland is de p16-Leiden mutatie (c.225-243del19), 
vernoemd naar de regio waar deze mutatie voor het eerst werd ontdekt. Naast CDKN2A is 
er één ander hoog penetrant melanoom risico gen geïdentificeerd. Mutaties in dit gen, 
CDK4, zijn wereldwijd in slechts enkele families gerapporteerd. Het verhoogde melanoom 
risico in de families zonder een mutatie in CDKN2A of CDK4 wordt grotendeels 
toegeschreven aan (combinaties van meerdere) medium- en laagrisico melanoom 
predispositie genen, waarvan er inmiddels diverse zijn geïdentificeerd.
De prognose van melanoompatiënten is sterk afhankelijk van het stadium ten tijde van de 
diagnose. Om vroegtijdige detectie van melanomen te bewerkstelligen, wordt geadviseerd 
de huid van leden van melanoom families periodiek te controleren (surveillance). Een veel 
gebruikt hulpmiddel bij de beoordeling van verdachte huidlaesies tijdens het huid-
onderzoek, is de dermatoscoop. Met dit niet-invasieve instrument is het mogelijk  structuren in 
de huid zichtbaar te maken die niet met het blote oog waarneembaar zijn. 
In dit proefschrift hebben we getracht meer inzicht te krijgen in de effectiviteit en aan-
knopingspunten voor optimalisatie van surveillance van families met een verhoogd 
melanoom risico, door onderzoek te doen naar:
1.  de klinisch en histologische kenmerken van melanoom(-patiënten) in deze families.
2.  de wijze waarop melanomen worden gedetecteerd in het surveillance programma
3.  de opbrengst van surveillance in relatie tot de kenmerken van de deelnemers en hun 
familie
4.  de rol van dermatoscopie in de praktijk van surveillance.
Klinisch en histologische kenmerken
In hoofdstuk 2 werden de klinische en histologische kenmerken van 429 melanomen van 
182 melanoompatiënten uit families met een p16-Leiden mutatie vergeleken met melanoom 
(patiënten) uit de algemene populatie.  
1 Deze definitie is afkomstig uit de Nederlandse richtlijn melanoom van de huid van 2005, die het uitgangspunt 
vormde van dit proefschrift. In de ge-update richtlijn uit 2012 is deze definitie verlaten en vangen door: 
"tenminste 3 melanomen, waarvan twee bij eerstegraads verwanten, waarbij twee tumoren mogen voor- 
komen bij één individu (de aangedane personen moeten dan ook eerstegraads verwanten zijn)"
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 Leden van p16-Leiden families hadden hun eerste melanoom op jongere leeftijd 
(gemiddeld 39 jaar, 15 jaar eerder dan de algemene bevolking) en een sterk verhoogd 
risico op multiple melanomen (5 en 10-jaars cumulatieve incidentie,  23% en 35%), vooral 
als het eerste melanoom op jonge leeftijd (< 40 jaar) werd gediagnostiseerd. Een associatie 
tussen de locatie van het eerste en tweede melanoom werd in de p16-populatie niet 
gevonden, in tegenstelling tot de algemene populatie, waarin dit wel het geval leek te 
zijn. P16-Leiden melanoom patiënten hadden relatief vaker een superficieel spreidend 
melanoom en minder lentigo maligna en nodulaire melanomen.  Melanomen in het 
hoofd hals gebied werden in de p16-Leiden populatie ten opzichte van melanomen op 
een andere locatie op een relatief jonge leeftijd gevonden, waar deze in de algemene 
populatie juist op relatief hoge leeftijd werden gediagnosticeerd. Deze bevindingen 
onderstrepen het belang van het starten van  surveillance van deze families op jonge 
leeftijd en geven aan dat extra waakzaamheid nodig is na de diagnose van een (eerste) 
melanoom. Daarnaast sluiten onze bevindingen goed aan bij recentere theorieën over de 
(klinisch, histologisch, epidemiologisch,  moleculaire) heterogeniteit van het melanoom 
en suggereren deze dat het verhoogde melanoom risico in p16-Leiden families mogelijk 
vooral bepaalde melanoom subtypen betreft (in het bijzonder die welke ontstaan volgens 
het zogenaamde “nevus pathway”, dat geassocieerd is met patiënten met veel 
moedervlekken en intermitterende zonblootstelling). Toekomstig onderzoek (zoals naar 
het genetische profiel van melanomen in deze families) moet uitwijzen in hoeverre dit 
beeld klopt en wat de consequenties hiervan zijn met betrekking tot preventie, prognose 
en behandeling.
Effectiviteit van surveillance
In hoofdstuk 3, 4 en 5 werd gekeken naar de effectiviteit van surveillance van melanoom 
families. In hoofdstuk 3 en 4 werd gevonden dat melanomen van verwanten uit 
melanoom families die deel namen aan het surveillance programma gunstigere 
prognostische kenmerken hadden (dunnere Breslow dikte) dan melanomen van de eerste 
verwanten uit de familie met een melanoom, die ten tijde van de diagnose geen deel 
namen aan surveillance. 
 In hoofdstuk 3 werd het moment van detectie van 226 melanomen van patiënten 
uit p16-Leiden families, die onder controle waren op de afdeling dermatologie van het 
Leids Universitair Medisch Centrum, onderzocht. Er werd gevonden dat 53% van alle 
melanomen werden gediagnosticeerd op reguliere huidcontroles. Zeven procent werd 
gevonden tijdens het allereerste huid-onderzoek, 20% tussen de vaste afspraken in 
(interval melanomen), en 20% werd gevonden bij patiënten die therapie ontrouw waren 
met betrekking tot de geadviseerde termijn tussen de huid controles.  Therapie ontrouw 
was vooral een frequent fenomeen bij patiënten bij wie voor het eerst een melanoom 
werd gediagnosticeerd (46%). Melanomen van therapie-ontrouwe verwanten hadden 
een dikkere Breslow dikte dan die van therapie-trouwe verwanten. Ook bleek dat de 
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meerderheid (58%) van de melanomen binnen 6 maanden na de laatste huidcontrole 
werden gevonden. Er werd echter geen correlatie gevonden tussen de Breslow dikte en 
de tijdsinterval tussen de huidcontroles, voor een interval korter dan 24 maanden.
In hoofdstuk 4 werd de opbrengst van surveillance in melanoom families met 
verschillende karakteristieken vergeleken. Er werd gevonden dat er significant meer 
melanomen werden gediagnosticeerd in families met de p16-Leiden mutatie in CDKN2A 
vergeleken bij families waarin geen mutatie in CDKN2A werd gevonden (hazard ratio (HR): 
3.6, 95% betrouwbaarheidsinterval (CI): 1.4 – 9.0 ). In een subanalyse van ongeteste en 
families zonder CDKN2A mutatie werd een net niet significant verschil gevonden tussen 
families met twee melanoom patiënten ten opzichte van families met drie of meer 
melanoom patiënten (HR (≥3 t.o.v. 2): 2.2, 95% CI: 0.9 – 5.0). Verder werd gevonden dat het 
risico op een (volgend) melanoom aanzienlijk groter was voor melanoompatiënten ten 
opzicht van hun eerstegraads verwanten (HR: 3.9, 95% CI: 2.0 – 7.7).
In hoofdstuk 5 werd de opbrengst van surveillance in tweedegraads verwanten van me-
lanoompatiënten uit families met een p16-Leiden mutatie onderzocht. Er werd een 
incidentie van 2.2 / 1000 persoonsjaren gevonden in de gehele groep van tweedegraads 
verwanten, en 8.5 / 1000 persoonsjaren voor tweedegraads verwanten die deelnamen 
aan surveillance. Dit verschil is mogelijk toe te schrijven aan een selectie bias van 
tweedegraads verwanten met een grotere kans op een melanoom bijvoorbeeld op 
grond van moedervlekkenpatroon. Ten opzichte van de algemene bevolking vonden we 
een ‘standardized morbidity ratio’ (SMR)voor het risico op melanoom voor tweedegraads 
verwanten van 12.9 (95% CI, 7.2-23.4).
Over-diagnostiek
De incidentie van het melanoom van de huid is de afgelopen decennia sterk toegenomen. 
Omdat de mortaliteit in dezelfde periode minder sterk is gestegen, terwijl de 
behandelopties tot zeer recent niet zijn verbeterd, is gesuggereerd dat de stijging in 
melanoom incidentie mogelijk gedeeltelijk is toe te schrijven aan over-diagnostiek: het 
diagnosticeren van melanocytaire tumoren met een indolent beloop als melanoom. 
Over-diagnostiek is een bekend fenomeen bij screening voor andere vormen van kanker 
(o.a. borstkanker).
 In hoofdstuk 6 rapporteerden we een observatie met betrekking tot over-diagnos-
tiek in melanoom families. Een patholoog met speciale expertise in de beoordeling van 
melanocytaire laesies reviseerde melanomen van leden van families waarin de p16-Leiden 
mutatie was gedetecteerd, geblindeerd voor de mutatie status van de individuele 
patiënten. Het is een herhaaldelijk gerapporteerd fenomeen dat in families met een 
CDKN2A mutatie vaker dan verwacht melanomen worden gediagnostiseerd bij verwanten die 
de mutatie zelf niet blijken te hebben. Het bleek in onze dataset dat bij 7 van 10 melanoom- 
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patiënten (met 8 melanomen, waarvan 7 in situ) zonder CDKN2A mutatie, de diagnose 
melanoom na revisie werd verworpen. Bij bewezen mutatiedragers gebeurde dit in 
een veel lager percentage (11%) van de melanomen. Dit illustreert dat bij surveillance 
van personen met een onterecht geanticipeerd sterk verhoogd melanoomrisico, over- 
diagnostiek een reëel risico vormt.
Dermatoscopie
In het laatste deel van het proefschrift (hoofdstuk 7 en 8) werd gekeken naar de invloed 
van dermatoscopie in de klinische praktijk.  Tientallen studies hebben aangetoond dat 
dermatoscopie de sensitiviteit en specificiteit van de diagnose  melanoom met het blote 
oog kan verbeteren. Er is echter minder bekend over de invloed van dermatoscopie op de 
beslissing om een verdachte gepigmenteerde laesie te excideren. Hiertoe werden twee 
studies verricht, respectievelijk (hoofdstuk 8) in de setting van een tertiaire pigmentpoli 
met dermatoscopie experts die hoog risico patiënten uit melanoom families controleerden 
en (hoofdstuk 7) in de setting van algemene dermatologen in perifere ziekenhuizen met 
een gemengde patiënten populatie.  
 Waar eerdere studies  suggereren dat het belangrijkste effect van dermatoscopie een 
verbetering van de sensitiviteit is, vonden wij in beide settings dat dermatoscopie vooral 
leidde tot een afname van het aantal onnodige excisies van goedaardige laesies. Dit effect 
was het grootst in de dermatoscopie expert / hoog-risico patiënten setting (42%) en 
resulteerde in een significante verbetering van de specificiteit (van 0.53 met het blote oog 
alleen, naar 0.74 bij toevoeging van de dermatoscoop). In de non-expert / algemene 
populatie setting werd een reductie van het aantal excisies van 9% gezien (zonder 
significante verbetering van de specificiteit (van 0.64 naar 0.68)). In onze studies had 
dermatoscopie geen (significant) effect op de sensitiviteit, al werd de bewijskracht van de 
studies om deze te detecteren beperkt door het kleine aantal melanomen in de studie.
Hoofdstuk 9 geeft een samenvatting en bediscussieert de resultaten uit de voorgaande 
hoofdstukken. Op grond van onze bevindingen werden adviezen gegeven ter optimalisering 
van het beleid ten aanzien van families met verhoogd risico op melanoom (tabel 2, 
Summary and Discussion).
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List of abbreviations
ALM  acral lentiginous melanoma
AN atypical nevi
BCC  basal cell carcinoma
CI  confidence interval
CMM  cutaneous malignant melanoma
FAMMM  familial atypical multiple mole-melanoma syndrome
FN  false negatives
FP  false positives
GEE  generalized estimation equations
HR  hazard ratio
LCR  Leiden cancer registry
LM  lentigo maligna
LMM  lentigo maligna melanoma
LUMC  Leiden university medical center
Mis  melanoma in situ
MPM  multiple primary melanomas
NEE  naked eye examination
NFDHT  Netherlands foundation for the detection of hereditary tumours
NM  nodular melanoma
NNS  number needed to screen
OR  odds ratio
PLC  pigmented lesion clinic
RR  relative risk
SK  seborrhoeic keratosis
SMR  standardized morbidity ratio
SSM  superficial spreading melanoma
TN  true negatives
TP  true positives
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